AU2020288563A1 - Imidazo(1,2-c)pyrimidine derivatives as PRC2 inhibitors for treating cancer - Google Patents

Info

Publication number

AU2020288563A1

AU2020288563A1 AU2020288563A AU2020288563A AU2020288563A1 AU 2020288563 A1 AU2020288563 A1 AU 2020288563A1 AU 2020288563 A AU2020288563 A AU 2020288563A AU 2020288563 A AU2020288563 A AU 2020288563A AU 2020288563 A1 AU2020288563 A1 AU 2020288563A1

Authority

AU

Australia

Prior art keywords

compound

methyl

equiv

heterocyclyl

mmol

Prior art date

2019-06-05

Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)

Abandoned

Links

• Espacenet
• Global Dossier
• Discuss

• 206010028980 Neoplasm Diseases 0.000 title claims abstract description 35
• 201000011510 cancer Diseases 0.000 title claims abstract description 21
• 101100465401 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) SCL1 gene Proteins 0.000 title claims 3
• 239000003112 inhibitor Substances 0.000 title description 11
• PQWQQQGKMHENOC-UHFFFAOYSA-N imidazo[1,2-c]pyrimidine Chemical class C1=NC=CC2=NC=CN21 PQWQQQGKMHENOC-UHFFFAOYSA-N 0.000 title description 4
• 150000001875 compounds Chemical class 0.000 claims abstract description 251
• 238000000034 method Methods 0.000 claims abstract description 31
• 230000000694 effects Effects 0.000 claims abstract description 26
• 239000008194 pharmaceutical composition Substances 0.000 claims abstract description 17
• -1 cyano, hydroxyl Chemical group 0.000 claims description 92
• 125000000217 alkyl group Chemical group 0.000 claims description 69
• 125000001072 heteroaryl group Chemical group 0.000 claims description 62
• 229910052757 nitrogen Inorganic materials 0.000 claims description 58
• 229910052739 hydrogen Inorganic materials 0.000 claims description 55
• 239000001257 hydrogen Substances 0.000 claims description 55
• 125000003118 aryl group Chemical group 0.000 claims description 51
• 229910052736 halogen Inorganic materials 0.000 claims description 49
• 150000002367 halogens Chemical class 0.000 claims description 49
• 210000004027 cell Anatomy 0.000 claims description 45
• 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 39
• 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 39
• 125000001188 haloalkyl group Chemical group 0.000 claims description 37
• 125000000623 heterocyclic group Chemical group 0.000 claims description 35
• 125000003545 alkoxy group Chemical group 0.000 claims description 28
• 125000000753 cycloalkyl group Chemical group 0.000 claims description 28
• 229910052760 oxygen Inorganic materials 0.000 claims description 27
• 150000003839 salts Chemical class 0.000 claims description 27
• 125000002768 hydroxyalkyl group Chemical group 0.000 claims description 25
• 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 25
• 125000004404 heteroalkyl group Chemical group 0.000 claims description 24
• UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 17
• 208000009956 adenocarcinoma Diseases 0.000 claims description 17
• 206010025323 Lymphomas Diseases 0.000 claims description 16
• 125000004193 piperazinyl group Chemical group 0.000 claims description 13
• 201000009030 Carcinoma Diseases 0.000 claims description 11
• 206010039491 Sarcoma Diseases 0.000 claims description 11
• 125000003710 aryl alkyl group Chemical group 0.000 claims description 11
• 125000004093 cyano group Chemical group *C#N 0.000 claims description 11
• 125000000719 pyrrolidinyl group Chemical group 0.000 claims description 11
• 125000002947 alkylene group Chemical group 0.000 claims description 10
• 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 10
• 206010041823 squamous cell carcinoma Diseases 0.000 claims description 10
• 125000002393 azetidinyl group Chemical group 0.000 claims description 9
• 230000005764 inhibitory process Effects 0.000 claims description 9
• 125000004043 oxo group Chemical group O=* 0.000 claims description 9
• 229920006395 saturated elastomer Polymers 0.000 claims description 9
• 206010024612 Lipoma Diseases 0.000 claims description 8
• 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 8
• 230000002401 inhibitory effect Effects 0.000 claims description 8
• 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims description 8
• 125000004076 pyridyl group Chemical group 0.000 claims description 8
• 125000004122 cyclic group Chemical group 0.000 claims description 7
• 229910052717 sulfur Inorganic materials 0.000 claims description 7
• 125000001412 tetrahydropyranyl group Chemical group 0.000 claims description 7
• 201000008808 Fibrosarcoma Diseases 0.000 claims description 6
• 206010043276 Teratoma Diseases 0.000 claims description 6
• 206010016629 fibroma Diseases 0.000 claims description 6
• 201000011066 hemangioma Diseases 0.000 claims description 6
• 125000005842 heteroatom Chemical group 0.000 claims description 6
• 125000002757 morpholinyl group Chemical group 0.000 claims description 6
• 125000003566 oxetanyl group Chemical group 0.000 claims description 6
• 125000003226 pyrazolyl group Chemical group 0.000 claims description 6
• 239000012453 solvate Substances 0.000 claims description 6
• 125000003718 tetrahydrofuranyl group Chemical group 0.000 claims description 6
• 125000003831 tetrazolyl group Chemical group 0.000 claims description 6
• 206010073071 hepatocellular carcinoma Diseases 0.000 claims description 5
• 125000004433 nitrogen atom Chemical group N* 0.000 claims description 5
• 125000002971 oxazolyl group Chemical group 0.000 claims description 5
• 210000002307 prostate Anatomy 0.000 claims description 5
• 125000000714 pyrimidinyl group Chemical group 0.000 claims description 5
• 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims description 5
• 201000003076 Angiosarcoma Diseases 0.000 claims description 4
• 208000032612 Glial tumor Diseases 0.000 claims description 4
• 206010018338 Glioma Diseases 0.000 claims description 4
• 208000002927 Hamartoma Diseases 0.000 claims description 4
• 208000001258 Hemangiosarcoma Diseases 0.000 claims description 4
• 208000007766 Kaposi sarcoma Diseases 0.000 claims description 4
• 208000018142 Leiomyosarcoma Diseases 0.000 claims description 4
• 208000034578 Multiple myelomas Diseases 0.000 claims description 4
• 208000015914 Non-Hodgkin lymphomas Diseases 0.000 claims description 4
• 206010035226 Plasma cell myeloma Diseases 0.000 claims description 4
• 208000008383 Wilms tumor Diseases 0.000 claims description 4
• 208000002458 carcinoid tumor Diseases 0.000 claims description 4
• 208000006990 cholangiocarcinoma Diseases 0.000 claims description 4
• 239000003085 diluting agent Substances 0.000 claims description 4
• 125000000842 isoxazolyl group Chemical group 0.000 claims description 4
• 201000010260 leiomyoma Diseases 0.000 claims description 4
• 201000001441 melanoma Diseases 0.000 claims description 4
• 206010027191 meningioma Diseases 0.000 claims description 4
• 201000008968 osteosarcoma Diseases 0.000 claims description 4
• 239000000546 pharmaceutical excipient Substances 0.000 claims description 4
• 125000003373 pyrazinyl group Chemical group 0.000 claims description 4
• 125000002098 pyridazinyl group Chemical group 0.000 claims description 4
• 125000000335 thiazolyl group Chemical group 0.000 claims description 4
• 125000004306 triazinyl group Chemical group 0.000 claims description 4
• 206010006187 Breast cancer Diseases 0.000 claims description 3
• 208000026310 Breast neoplasm Diseases 0.000 claims description 3
• 210000004556 brain Anatomy 0.000 claims description 3
• 239000003937 drug carrier Substances 0.000 claims description 3
• 230000002496 gastric effect Effects 0.000 claims description 3
• 125000002883 imidazolyl group Chemical group 0.000 claims description 3
• 210000004185 liver Anatomy 0.000 claims description 3
• 210000004072 lung Anatomy 0.000 claims description 3
• 210000000496 pancreas Anatomy 0.000 claims description 3
• 208000024893 Acute lymphoblastic leukemia Diseases 0.000 claims description 2
• 208000014697 Acute lymphocytic leukaemia Diseases 0.000 claims description 2
• 206010001233 Adenoma benign Diseases 0.000 claims description 2
• 206010003571 Astrocytoma Diseases 0.000 claims description 2
• 208000010839 B-cell chronic lymphocytic leukemia Diseases 0.000 claims description 2
• 206010004146 Basal cell carcinoma Diseases 0.000 claims description 2
• 206010073106 Bone giant cell tumour malignant Diseases 0.000 claims description 2
• 208000009458 Carcinoma in Situ Diseases 0.000 claims description 2
• 201000005262 Chondroma Diseases 0.000 claims description 2
• 208000005243 Chondrosarcoma Diseases 0.000 claims description 2
• 201000009047 Chordoma Diseases 0.000 claims description 2
• 208000006332 Choriocarcinoma Diseases 0.000 claims description 2
• 206010048832 Colon adenoma Diseases 0.000 claims description 2
• 206010010356 Congenital anomaly Diseases 0.000 claims description 2
• 208000007033 Dysgerminoma Diseases 0.000 claims description 2
• 208000000471 Dysplastic Nevus Syndrome Diseases 0.000 claims description 2
• 201000009051 Embryonal Carcinoma Diseases 0.000 claims description 2
• 206010014967 Ependymoma Diseases 0.000 claims description 2
• VGGSQFUCUMXWEO-UHFFFAOYSA-N Ethene Chemical compound C=C VGGSQFUCUMXWEO-UHFFFAOYSA-N 0.000 claims description 2
• 239000005977 Ethylene Substances 0.000 claims description 2
• 208000006168 Ewing Sarcoma Diseases 0.000 claims description 2
• 208000007659 Fibroadenoma Diseases 0.000 claims description 2
• 206010053717 Fibrous histiocytoma Diseases 0.000 claims description 2
• 208000000527 Germinoma Diseases 0.000 claims description 2
• 208000007569 Giant Cell Tumors Diseases 0.000 claims description 2
• 201000005409 Gliomatosis cerebri Diseases 0.000 claims description 2
• 206010018404 Glucagonoma Diseases 0.000 claims description 2
• 206010018691 Granuloma Diseases 0.000 claims description 2
• 206010019629 Hepatic adenoma Diseases 0.000 claims description 2
• 208000017604 Hodgkin disease Diseases 0.000 claims description 2
• 208000005045 Interdigitating dendritic cell sarcoma Diseases 0.000 claims description 2
• 208000002260 Keloid Diseases 0.000 claims description 2
• 208000002404 Liver Cell Adenoma Diseases 0.000 claims description 2
• 208000031422 Lymphocytic Chronic B-Cell Leukemia Diseases 0.000 claims description 2
• 208000006644 Malignant Fibrous Histiocytoma Diseases 0.000 claims description 2
• 208000000172 Medulloblastoma Diseases 0.000 claims description 2
• 206010027406 Mesothelioma Diseases 0.000 claims description 2
• 201000003793 Myelodysplastic syndrome Diseases 0.000 claims description 2
• 208000014767 Myeloproliferative disease Diseases 0.000 claims description 2
• 206010029260 Neuroblastoma Diseases 0.000 claims description 2
• 201000004404 Neurofibroma Diseases 0.000 claims description 2
• 201000010133 Oligodendroglioma Diseases 0.000 claims description 2
• 208000010191 Osteitis Deformans Diseases 0.000 claims description 2
• 208000000035 Osteochondroma Diseases 0.000 claims description 2
• 208000027067 Paget disease of bone Diseases 0.000 claims description 2
• 206010061902 Pancreatic neoplasm Diseases 0.000 claims description 2
• 208000007641 Pinealoma Diseases 0.000 claims description 2
• 208000006664 Precursor Cell Lymphoblastic Leukemia-Lymphoma Diseases 0.000 claims description 2
• 206010060862 Prostate cancer Diseases 0.000 claims description 2
• 208000000236 Prostatic Neoplasms Diseases 0.000 claims description 2
• 201000004681 Psoriasis Diseases 0.000 claims description 2
• 201000000582 Retinoblastoma Diseases 0.000 claims description 2
• 208000005678 Rhabdomyoma Diseases 0.000 claims description 2
• 201000010208 Seminoma Diseases 0.000 claims description 2
• 208000000097 Sertoli-Leydig cell tumor Diseases 0.000 claims description 2
• 208000000453 Skin Neoplasms Diseases 0.000 claims description 2
• 208000015778 Undifferentiated pleomorphic sarcoma Diseases 0.000 claims description 2
• 208000009311 VIPoma Diseases 0.000 claims description 2
• 206010048214 Xanthoma Diseases 0.000 claims description 2
• 206010048215 Xanthomatosis Diseases 0.000 claims description 2
• 230000001154 acute effect Effects 0.000 claims description 2
• 208000002718 adenomatoid tumor Diseases 0.000 claims description 2
• 210000004100 adrenal gland Anatomy 0.000 claims description 2
• 201000007434 ampulla of Vater carcinoma Diseases 0.000 claims description 2
• 208000001119 benign fibrous histiocytoma Diseases 0.000 claims description 2
• 210000003445 biliary tract Anatomy 0.000 claims description 2
• 210000004369 blood Anatomy 0.000 claims description 2
• 239000008280 blood Substances 0.000 claims description 2
• 208000016738 bone Paget disease Diseases 0.000 claims description 2
• 210000000988 bone and bone Anatomy 0.000 claims description 2
• 201000009480 botryoid rhabdomyosarcoma Diseases 0.000 claims description 2
• 201000003149 breast fibroadenoma Diseases 0.000 claims description 2
• 208000003362 bronchogenic carcinoma Diseases 0.000 claims description 2
• 201000002143 bronchus adenoma Diseases 0.000 claims description 2
• 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 claims description 2
• 208000011825 carcinoma of the ampulla of vater Diseases 0.000 claims description 2
• 230000000747 cardiac effect Effects 0.000 claims description 2
• 201000005217 chondroblastoma Diseases 0.000 claims description 2
• 230000001684 chronic effect Effects 0.000 claims description 2
• 208000032852 chronic lymphocytic leukemia Diseases 0.000 claims description 2
• 208000009060 clear cell adenocarcinoma Diseases 0.000 claims description 2
• 201000010305 cutaneous fibrous histiocytoma Diseases 0.000 claims description 2
• 208000035250 cutaneous malignant susceptibility to 1 melanoma Diseases 0.000 claims description 2
• 201000009409 embryonal rhabdomyosarcoma Diseases 0.000 claims description 2
• 230000002357 endometrial effect Effects 0.000 claims description 2
• 210000003238 esophagus Anatomy 0.000 claims description 2
• 201000010175 gallbladder cancer Diseases 0.000 claims description 2
• 201000007487 gallbladder carcinoma Diseases 0.000 claims description 2
• 208000015419 gastrin-producing neuroendocrine tumor Diseases 0.000 claims description 2
• 201000000052 gastrinoma Diseases 0.000 claims description 2
• 201000003115 germ cell cancer Diseases 0.000 claims description 2
• 208000005017 glioblastoma Diseases 0.000 claims description 2
• 201000010536 head and neck cancer Diseases 0.000 claims description 2
• 208000014829 head and neck neoplasm Diseases 0.000 claims description 2
• 230000002489 hematologic effect Effects 0.000 claims description 2
• 208000006359 hepatoblastoma Diseases 0.000 claims description 2
• 201000002735 hepatocellular adenoma Diseases 0.000 claims description 2
• 231100000844 hepatocellular carcinoma Toxicity 0.000 claims description 2
• 201000004933 in situ carcinoma Diseases 0.000 claims description 2
• 206010022498 insulinoma Diseases 0.000 claims description 2
• 210000002570 interstitial cell Anatomy 0.000 claims description 2
• 201000010985 invasive ductal carcinoma Diseases 0.000 claims description 2
• 125000004594 isoindolinyl group Chemical group C1(NCC2=CC=CC=C12)* 0.000 claims description 2
• 210000001117 keloid Anatomy 0.000 claims description 2
• 210000003734 kidney Anatomy 0.000 claims description 2
• 208000022013 kidney Wilms tumor Diseases 0.000 claims description 2
• 208000032839 leukemia Diseases 0.000 claims description 2
• 206010024627 liposarcoma Diseases 0.000 claims description 2
• 208000014018 liver neoplasm Diseases 0.000 claims description 2
• 201000004593 malignant giant cell tumor Diseases 0.000 claims description 2
• 201000000289 malignant teratoma Diseases 0.000 claims description 2
• 210000002418 meninge Anatomy 0.000 claims description 2
• 208000010492 mucinous cystadenocarcinoma Diseases 0.000 claims description 2
• 208000025113 myeloid leukemia Diseases 0.000 claims description 2
• 208000009091 myxoma Diseases 0.000 claims description 2
• 201000008026 nephroblastoma Diseases 0.000 claims description 2
• 210000000653 nervous system Anatomy 0.000 claims description 2
• 208000007538 neurilemmoma Diseases 0.000 claims description 2
• 201000004662 neurofibroma of spinal cord Diseases 0.000 claims description 2
• 208000004649 neutrophil actin dysfunction Diseases 0.000 claims description 2
• 208000003388 osteoid osteoma Diseases 0.000 claims description 2
• 208000008798 osteoma Diseases 0.000 claims description 2
• 210000003101 oviduct Anatomy 0.000 claims description 2
• 208000021255 pancreatic insulinoma Diseases 0.000 claims description 2
• 125000001147 pentyl group Chemical group C(CCCC)* 0.000 claims description 2
• 208000024724 pineal body neoplasm Diseases 0.000 claims description 2
• 201000004123 pineal gland cancer Diseases 0.000 claims description 2
• 208000029922 reticulum cell sarcoma Diseases 0.000 claims description 2
• 201000009410 rhabdomyosarcoma Diseases 0.000 claims description 2
• 206010039667 schwannoma Diseases 0.000 claims description 2
• 210000003625 skull Anatomy 0.000 claims description 2
• 210000002784 stomach Anatomy 0.000 claims description 2
• 208000001608 teratocarcinoma Diseases 0.000 claims description 2
• 210000001550 testis Anatomy 0.000 claims description 2
• 206010044412 transitional cell carcinoma Diseases 0.000 claims description 2
• 208000022271 tubular adenoma Diseases 0.000 claims description 2
• 210000003708 urethra Anatomy 0.000 claims description 2
• 210000004291 uterus Anatomy 0.000 claims description 2
• 210000001215 vagina Anatomy 0.000 claims description 2
• 208000009540 villous adenoma Diseases 0.000 claims description 2
• 210000003905 vulva Anatomy 0.000 claims description 2
• 150000002431 hydrogen Chemical group 0.000 claims 8
• 125000000325 methylidene group Chemical group [H]C([H])=* 0.000 claims 5
• 125000004605 1,2,3,4-tetrahydroisoquinolinyl group Chemical group C1(NCCC2=CC=CC=C12)* 0.000 claims 1
• 206010005003 Bladder cancer Diseases 0.000 claims 1
• 208000010747 Hodgkins lymphoma Diseases 0.000 claims 1
• 208000007097 Urinary Bladder Neoplasms Diseases 0.000 claims 1
• 201000007270 liver cancer Diseases 0.000 claims 1
• 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims 1
• 201000002528 pancreatic cancer Diseases 0.000 claims 1
• 208000008443 pancreatic carcinoma Diseases 0.000 claims 1
• HNJBEVLQSNELDL-UHFFFAOYSA-N pyrrolidin-2-one Chemical compound O=C1CCCN1 HNJBEVLQSNELDL-UHFFFAOYSA-N 0.000 claims 1
• 208000004548 serous cystadenocarcinoma Diseases 0.000 claims 1
• 201000000849 skin cancer Diseases 0.000 claims 1
• 201000005112 urinary bladder cancer Diseases 0.000 claims 1
• 102000002272 Polycomb Repressive Complex 2 Human genes 0.000 abstract description 58
• 108010000597 Polycomb Repressive Complex 2 Proteins 0.000 abstract description 58
• XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 403
• 239000000203 mixture Substances 0.000 description 315
• 239000000543 intermediate Substances 0.000 description 201
• RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 197
• OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 153
• 235000019439 ethyl acetate Nutrition 0.000 description 139
• 239000000243 solution Substances 0.000 description 138
• 239000007787 solid Substances 0.000 description 132
• YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 126
• 238000005160 1H NMR spectroscopy Methods 0.000 description 124
• IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 106
• HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 103
• VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 101
• 239000011541 reaction mixture Substances 0.000 description 101
• XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 98
• 238000004895 liquid chromatography mass spectrometry Methods 0.000 description 96
• IAZDPXIOMUYVGZ-WFGJKAKNSA-N Dimethyl sulfoxide Chemical compound [2H]C([2H])([2H])S(=O)C([2H])([2H])[2H] IAZDPXIOMUYVGZ-WFGJKAKNSA-N 0.000 description 94
• 239000003208 petroleum Substances 0.000 description 94
• WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 86
• 230000002829 reductive effect Effects 0.000 description 79
• ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 72
• 239000003921 oil Substances 0.000 description 68
• 238000006243 chemical reaction Methods 0.000 description 66
• PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 61
• 239000012267 brine Substances 0.000 description 56
• HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 56
• 238000004440 column chromatography Methods 0.000 description 51
• SCVFZCLFOSHCOH-UHFFFAOYSA-M potassium acetate Chemical compound [K+].CC([O-])=O SCVFZCLFOSHCOH-UHFFFAOYSA-M 0.000 description 50
• 229910052681 coesite Inorganic materials 0.000 description 49
• 229910052906 cristobalite Inorganic materials 0.000 description 49
• 239000000377 silicon dioxide Substances 0.000 description 49
• 229910052682 stishovite Inorganic materials 0.000 description 49
• 229910052905 tridymite Inorganic materials 0.000 description 49
• KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 47
• OKKJLVBELUTLKV-MZCSYVLQSA-N Deuterated methanol Chemical compound [2H]OC([2H])([2H])[2H] OKKJLVBELUTLKV-MZCSYVLQSA-N 0.000 description 43
• 239000012074 organic phase Substances 0.000 description 40
• RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 37
• 102100038970 Histone-lysine N-methyltransferase EZH2 Human genes 0.000 description 35
• 101710196274 Histone-lysine N-methyltransferase EZH2 Proteins 0.000 description 35
• KZPYGQFFRCFCPP-UHFFFAOYSA-N 1,1'-bis(diphenylphosphino)ferrocene Chemical compound [Fe+2].C1=CC=C[C-]1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=C[C-]1P(C=1C=CC=CC=1)C1=CC=CC=C1 KZPYGQFFRCFCPP-UHFFFAOYSA-N 0.000 description 33
• KZBUYRJDOAKODT-UHFFFAOYSA-N Chlorine Chemical compound ClCl KZBUYRJDOAKODT-UHFFFAOYSA-N 0.000 description 32
• 239000012299 nitrogen atmosphere Substances 0.000 description 31
• 239000012071 phase Substances 0.000 description 31
• JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 29
• 239000013058 crude material Substances 0.000 description 28
• 229910052938 sodium sulfate Inorganic materials 0.000 description 28
• DYHSDKLCOJIUFX-UHFFFAOYSA-N tert-butoxycarbonyl anhydride Chemical compound CC(C)(C)OC(=O)OC(=O)OC(C)(C)C DYHSDKLCOJIUFX-UHFFFAOYSA-N 0.000 description 28
• UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical class [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 27
• HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 27
• BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 27
• QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 26
• NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical compound [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 26
• 239000012044 organic layer Substances 0.000 description 24
• 235000011056 potassium acetate Nutrition 0.000 description 24
• 235000011152 sodium sulphate Nutrition 0.000 description 24
• 239000011737 fluorine Substances 0.000 description 23
• 229910052731 fluorine Inorganic materials 0.000 description 23
• DTQVDTLACAAQTR-UHFFFAOYSA-N trifluoroacetic acid Substances OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 23
• IPWKHHSGDUIRAH-UHFFFAOYSA-N bis(pinacolato)diboron Chemical compound O1C(C)(C)C(C)(C)OB1B1OC(C)(C)C(C)(C)O1 IPWKHHSGDUIRAH-UHFFFAOYSA-N 0.000 description 22
• YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 21
• 235000012239 silicon dioxide Nutrition 0.000 description 21
• ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 20
• 239000012298 atmosphere Substances 0.000 description 20
• 239000000725 suspension Substances 0.000 description 18
• IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 17
• 108010033040 Histones Proteins 0.000 description 17
• VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 17
• 239000000706 filtrate Substances 0.000 description 16
• 238000002953 preparative HPLC Methods 0.000 description 16
• 238000003756 stirring Methods 0.000 description 16
• LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 15
• 239000008346 aqueous phase Substances 0.000 description 15
• 239000012065 filter cake Substances 0.000 description 15
• 125000001153 fluoro group Chemical group F* 0.000 description 15
• 102100033636 Histone H3.2 Human genes 0.000 description 14
• 125000001424 substituent group Chemical group 0.000 description 14
• 235000019270 ammonium chloride Nutrition 0.000 description 13
• 229910000027 potassium carbonate Inorganic materials 0.000 description 13
• 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 12
• 238000000746 purification Methods 0.000 description 12
• 229910000030 sodium bicarbonate Inorganic materials 0.000 description 12
• VHYFNPMBLIVWCW-UHFFFAOYSA-N 4-Dimethylaminopyridine Chemical compound CN(C)C1=CC=NC=C1 VHYFNPMBLIVWCW-UHFFFAOYSA-N 0.000 description 11
• 235000011181 potassium carbonates Nutrition 0.000 description 11
• 235000017557 sodium bicarbonate Nutrition 0.000 description 11
• CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 10
• 230000035772 mutation Effects 0.000 description 10
• XHXFXVLFKHQFAL-UHFFFAOYSA-N phosphoryl trichloride Chemical compound ClP(Cl)(Cl)=O XHXFXVLFKHQFAL-UHFFFAOYSA-N 0.000 description 10
• 239000011369 resultant mixture Substances 0.000 description 10
• 238000010626 work up procedure Methods 0.000 description 10
• LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 9
• 239000007832 Na2SO4 Substances 0.000 description 9
• 239000000460 chlorine Substances 0.000 description 9
• MZRVEZGGRBJDDB-UHFFFAOYSA-N n-Butyllithium Substances [Li]CCCC MZRVEZGGRBJDDB-UHFFFAOYSA-N 0.000 description 9
• YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 9
• MFYSUUPKMDJYPF-UHFFFAOYSA-N 2-[(4-methyl-2-nitrophenyl)diazenyl]-3-oxo-n-phenylbutanamide Chemical compound C=1C=CC=CC=1NC(=O)C(C(=O)C)N=NC1=CC=C(C)C=C1[N+]([O-])=O MFYSUUPKMDJYPF-UHFFFAOYSA-N 0.000 description 8
• WEROVYOUOIXAEC-UHFFFAOYSA-N 8-bromo-5-[(5-fluoro-2,3-dihydro-1-benzofuran-4-yl)methylamino]imidazo[1,2-c]pyrimidine-2-carbonitrile Chemical compound FC1=C(CNC2=NC=C(Br)C3=NC(=CN23)C#N)C2=C(OCC2)C=C1 WEROVYOUOIXAEC-UHFFFAOYSA-N 0.000 description 8
• ROSDSFDQCJNGOL-UHFFFAOYSA-N Dimethylamine Chemical compound CNC ROSDSFDQCJNGOL-UHFFFAOYSA-N 0.000 description 8
• 102000004190 Enzymes Human genes 0.000 description 8
• 108090000790 Enzymes Proteins 0.000 description 8
• PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 8
• NFHFRUOZVGFOOS-UHFFFAOYSA-N Pd(PPh3)4 Substances [Pd].C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 NFHFRUOZVGFOOS-UHFFFAOYSA-N 0.000 description 8
• 230000003213 activating effect Effects 0.000 description 8
• 229910052801 chlorine Inorganic materials 0.000 description 8
• 239000012230 colorless oil Substances 0.000 description 8
• 206010012818 diffuse large B-cell lymphoma Diseases 0.000 description 8
• 235000019441 ethanol Nutrition 0.000 description 8
• 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 8
• 239000002904 solvent Substances 0.000 description 8
• 238000011282 treatment Methods 0.000 description 8
• WZHOBXRNVCZJGB-UHFFFAOYSA-N 1,3-dimethyl-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyrazole Chemical compound CN1N=C(C)C=C1B1OC(C)(C)C(C)(C)O1 WZHOBXRNVCZJGB-UHFFFAOYSA-N 0.000 description 7
• BPTQDIYJVPPMKF-UHFFFAOYSA-N 4-bromo-5-fluoro-1-benzofuran Chemical compound FC1=CC=C2OC=CC2=C1Br BPTQDIYJVPPMKF-UHFFFAOYSA-N 0.000 description 7
• MHLGMBQJMKRTOH-UHFFFAOYSA-N CN1N=C(C=C1C=1C=2N(C(=NC=1)NCC1=C(C=CC3=C1CCO3)F)C=C(N=2)C=O)C Chemical compound CN1N=C(C=C1C=1C=2N(C(=NC=1)NCC1=C(C=CC3=C1CCO3)F)C=C(N=2)C=O)C MHLGMBQJMKRTOH-UHFFFAOYSA-N 0.000 description 7
• CHOZNSNAPKIXKZ-UHFFFAOYSA-N FC1=CC=C2C(C=CO2)=C1C#N Chemical compound FC1=CC=C2C(C=CO2)=C1C#N CHOZNSNAPKIXKZ-UHFFFAOYSA-N 0.000 description 7
• 208000031671 Large B-Cell Diffuse Lymphoma Diseases 0.000 description 7
• 239000007864 aqueous solution Substances 0.000 description 7
• POJLFXSHDKTYNB-UHFFFAOYSA-N ethyl 8-bromo-5-[(5-fluoro-2,3-dihydro-1-benzofuran-4-yl)methylamino]imidazo[1,2-c]pyrimidine-2-carboxylate Chemical compound CCOC(=O)C1=CN2C(=N1)C(Br)=CN=C2NCC1=C(F)C=CC2=C1CCO2 POJLFXSHDKTYNB-UHFFFAOYSA-N 0.000 description 7
• 125000001570 methylene group Chemical group [H]C([H])([*:1])[*:2] 0.000 description 7
• 108090000623 proteins and genes Proteins 0.000 description 7
• 238000010898 silica gel chromatography Methods 0.000 description 7
• 239000003643 water by type Substances 0.000 description 7
• WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 6
• QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 6
• VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 6
• ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 6
• HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 6
• ZQCBMJUJKIMNNW-UHFFFAOYSA-N ClC1=NC=C(Br)C2=NC(=CN12)C#N Chemical compound ClC1=NC=C(Br)C2=NC(=CN12)C#N ZQCBMJUJKIMNNW-UHFFFAOYSA-N 0.000 description 6
• 239000007821 HATU Substances 0.000 description 6
• XLYOFNOQVPJJNP-ZSJDYOACSA-N Heavy water Chemical compound [2H]O[2H] XLYOFNOQVPJJNP-ZSJDYOACSA-N 0.000 description 6
• 235000011054 acetic acid Nutrition 0.000 description 6
• 150000001412 amines Chemical class 0.000 description 6
• 238000003556 assay Methods 0.000 description 6
• 201000010099 disease Diseases 0.000 description 6
• 208000035475 disorder Diseases 0.000 description 6
• 238000001914 filtration Methods 0.000 description 6
• 230000001404 mediated effect Effects 0.000 description 6
• 125000006413 ring segment Chemical group 0.000 description 6
• 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 6
• QAEDZJGFFMLHHQ-UHFFFAOYSA-N trifluoroacetic anhydride Chemical compound FC(F)(F)C(=O)OC(=O)C(F)(F)F QAEDZJGFFMLHHQ-UHFFFAOYSA-N 0.000 description 6
• 229960000549 4-dimethylaminophenol Drugs 0.000 description 5
• GMCYYKBDLFNEDH-UHFFFAOYSA-N CCOC(=O)C1=CN2C(=N1)C(Br)=CN=C2Cl Chemical compound CCOC(=O)C1=CN2C(=N1)C(Br)=CN=C2Cl GMCYYKBDLFNEDH-UHFFFAOYSA-N 0.000 description 5
• KXDHJXZQYSOELW-UHFFFAOYSA-M Carbamate Chemical compound NC([O-])=O KXDHJXZQYSOELW-UHFFFAOYSA-M 0.000 description 5
• ALWPRZGDSFAJQS-UHFFFAOYSA-N FC=1C=CC2=C(CCO2)C=1CN Chemical compound FC=1C=CC2=C(CCO2)C=1CN ALWPRZGDSFAJQS-UHFFFAOYSA-N 0.000 description 5
• WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 5
• BZLVMXJERCGZMT-UHFFFAOYSA-N Methyl tert-butyl ether Chemical compound COC(C)(C)C BZLVMXJERCGZMT-UHFFFAOYSA-N 0.000 description 5
• ZHACWBUGLHZPCX-UHFFFAOYSA-N NCC=1N=C2N(C(=NC=C2C2=CC(=NN2C)C)NCC2=C(C=CC3=C2CCO3)F)C=1 Chemical compound NCC=1N=C2N(C(=NC=C2C2=CC(=NN2C)C)NCC2=C(C=CC3=C2CCO3)F)C=1 ZHACWBUGLHZPCX-UHFFFAOYSA-N 0.000 description 5
• MHABMANUFPZXEB-UHFFFAOYSA-N O-demethyl-aloesaponarin I Natural products O=C1C2=CC=CC(O)=C2C(=O)C2=C1C=C(O)C(C(O)=O)=C2C MHABMANUFPZXEB-UHFFFAOYSA-N 0.000 description 5
• 125000004429 atom Chemical group 0.000 description 5
• FJDQFPXHSGXQBY-UHFFFAOYSA-L caesium carbonate Chemical compound [Cs+].[Cs+].[O-]C([O-])=O FJDQFPXHSGXQBY-UHFFFAOYSA-L 0.000 description 5
• 125000004432 carbon atom Chemical group C* 0.000 description 5
• 238000012512 characterization method Methods 0.000 description 5
• 239000003153 chemical reaction reagent Substances 0.000 description 5
• UAOMVDZJSHZZME-UHFFFAOYSA-N diisopropylamine Chemical compound CC(C)NC(C)C UAOMVDZJSHZZME-UHFFFAOYSA-N 0.000 description 5
• 230000002255 enzymatic effect Effects 0.000 description 5
• JLQPWNMJSJOARH-UHFFFAOYSA-N ethyl 8-bromo-5-oxo-6H-imidazo[1,2-c]pyrimidine-2-carboxylate Chemical compound CCOC(=O)C1=CN2C(=N1)C(Br)=CNC2=O JLQPWNMJSJOARH-UHFFFAOYSA-N 0.000 description 5
• DLEDOFVPSDKWEF-UHFFFAOYSA-N lithium butane Chemical compound [Li+].CCC[CH2-] DLEDOFVPSDKWEF-UHFFFAOYSA-N 0.000 description 5
• 239000002244 precipitate Substances 0.000 description 5
• 229910000029 sodium carbonate Inorganic materials 0.000 description 5
• 229910000104 sodium hydride Inorganic materials 0.000 description 5
• LILXDMFJXYAKMK-UHFFFAOYSA-N 2-bromo-1,1-diethoxyethane Chemical compound CCOC(CBr)OCC LILXDMFJXYAKMK-UHFFFAOYSA-N 0.000 description 4
• LIXKPOLDKKJLFD-UHFFFAOYSA-N 2-bromo-4-(2,2-diethoxyethoxy)-1-fluorobenzene Chemical compound CCOC(OCC)COC1=CC=C(F)C(Br)=C1 LIXKPOLDKKJLFD-UHFFFAOYSA-N 0.000 description 4
• NDJPXOFQIJCADG-UHFFFAOYSA-N 4,4,5,5-tetramethyl-2-(2-methyl-4-methylsulfonylphenyl)-1,3,2-dioxaborolane Chemical compound CC1=CC(S(C)(=O)=O)=CC=C1B1OC(C)(C)C(C)(C)O1 NDJPXOFQIJCADG-UHFFFAOYSA-N 0.000 description 4
• QFVKLKDEXOWFSL-UHFFFAOYSA-N 6-amino-5-bromo-1h-pyrimidin-2-one Chemical compound NC=1NC(=O)N=CC=1Br QFVKLKDEXOWFSL-UHFFFAOYSA-N 0.000 description 4
• CYQRQBZIFMXUGJ-UHFFFAOYSA-N 6-bromo-5-fluoro-1-benzofuran Chemical compound C1=C(Br)C(F)=CC2=C1OC=C2 CYQRQBZIFMXUGJ-UHFFFAOYSA-N 0.000 description 4
• CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 4
• KPSWTZWRVRMIBS-UHFFFAOYSA-N BrC=1C=2N(C(=NC=1)NCC1=C(C=CC3=C1CCO3)F)C=C(N=2)C(C)NC(OC(C)(C)C)=O Chemical compound BrC=1C=2N(C(=NC=1)NCC1=C(C=CC3=C1CCO3)F)C=C(N=2)C(C)NC(OC(C)(C)C)=O KPSWTZWRVRMIBS-UHFFFAOYSA-N 0.000 description 4
• ZHVJJGTZTHPIKP-UHFFFAOYSA-N CCOC(=O)C1=CN2C(=N1)C(=CN=C2NCC1=C(F)C=CC2=C1CCO2)C1=CC(C)=NN1C Chemical compound CCOC(=O)C1=CN2C(=N1)C(=CN=C2NCC1=C(F)C=CC2=C1CCO2)C1=CC(C)=NN1C ZHVJJGTZTHPIKP-UHFFFAOYSA-N 0.000 description 4
• MVVTWFGQXKRKAK-UHFFFAOYSA-N CN1N=C(C=C1C=1C=2N(C(=NC=1)NCC1=C(C=CC3=C1CCO3)F)C=C(N=2)CO)C Chemical compound CN1N=C(C=C1C=1C=2N(C(=NC=1)NCC1=C(C=CC3=C1CCO3)F)C=C(N=2)CO)C MVVTWFGQXKRKAK-UHFFFAOYSA-N 0.000 description 4
• YZCKVEUIGOORGS-OUBTZVSYSA-N Deuterium Chemical compound [2H] YZCKVEUIGOORGS-OUBTZVSYSA-N 0.000 description 4
• 101000866766 Homo sapiens Polycomb protein EED Proteins 0.000 description 4
• KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 4
• CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 4
• WYTLIZJKOGIVKV-UHFFFAOYSA-N NC(=O)C1=CN2C(=N1)C(Br)=CN=C2NCC1=C(F)C=CC2=C1CCO2 Chemical compound NC(=O)C1=CN2C(=N1)C(Br)=CN=C2NCC1=C(F)C=CC2=C1CCO2 WYTLIZJKOGIVKV-UHFFFAOYSA-N 0.000 description 4
• DSRDXCDCNGVDOF-UHFFFAOYSA-N NC(=O)C1=CN2C(=N1)C(Br)=CNC2=O Chemical compound NC(=O)C1=CN2C(=N1)C(Br)=CNC2=O DSRDXCDCNGVDOF-UHFFFAOYSA-N 0.000 description 4
• SBSBLZNEENGEDP-UHFFFAOYSA-N OC(=O)C1=CN2C(=N1)C(Br)=CN=C2NCC1=C(F)C=CC2=C1CCO2 Chemical compound OC(=O)C1=CN2C(=N1)C(Br)=CN=C2NCC1=C(F)C=CC2=C1CCO2 SBSBLZNEENGEDP-UHFFFAOYSA-N 0.000 description 4
• BZMASMLCOWAKNJ-UHFFFAOYSA-N OC(=O)C1=CN2C(=N1)C(Br)=CNC2=O Chemical compound OC(=O)C1=CN2C(=N1)C(Br)=CNC2=O BZMASMLCOWAKNJ-UHFFFAOYSA-N 0.000 description 4
• 229910019213 POCl3 Inorganic materials 0.000 description 4
• OFBQJSOFQDEBGM-UHFFFAOYSA-N Pentane Chemical compound CCCCC OFBQJSOFQDEBGM-UHFFFAOYSA-N 0.000 description 4
• 102100031338 Polycomb protein EED Human genes 0.000 description 4
• NPXOKRUENSOPAO-UHFFFAOYSA-N Raney nickel Chemical compound [Al].[Ni] NPXOKRUENSOPAO-UHFFFAOYSA-N 0.000 description 4
• 125000003342 alkenyl group Chemical group 0.000 description 4
• 125000000304 alkynyl group Chemical group 0.000 description 4
• 239000000908 ammonium hydroxide Substances 0.000 description 4
• WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 4
• 210000000481 breast Anatomy 0.000 description 4
• 229910000024 caesium carbonate Inorganic materials 0.000 description 4
• 238000004587 chromatography analysis Methods 0.000 description 4
• 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 description 4
• NKLCNNUWBJBICK-UHFFFAOYSA-N dess–martin periodinane Chemical compound C1=CC=C2I(OC(=O)C)(OC(C)=O)(OC(C)=O)OC(=O)C2=C1 NKLCNNUWBJBICK-UHFFFAOYSA-N 0.000 description 4
• 229910052805 deuterium Inorganic materials 0.000 description 4
• 238000004108 freeze drying Methods 0.000 description 4
• 230000014509 gene expression Effects 0.000 description 4
• 238000004128 high performance liquid chromatography Methods 0.000 description 4
• INQOMBQAUSQDDS-UHFFFAOYSA-N iodomethane Chemical compound IC INQOMBQAUSQDDS-UHFFFAOYSA-N 0.000 description 4
• 230000011987 methylation Effects 0.000 description 4
• 238000007069 methylation reaction Methods 0.000 description 4
• YBYRMVIVWMBXKQ-UHFFFAOYSA-N phenylmethanesulfonyl fluoride Chemical compound FS(=O)(=O)CC1=CC=CC=C1 YBYRMVIVWMBXKQ-UHFFFAOYSA-N 0.000 description 4
• 238000013207 serial dilution Methods 0.000 description 4
• 239000012279 sodium borohydride Substances 0.000 description 4
• 229910000033 sodium borohydride Inorganic materials 0.000 description 4
• BEOOHQFXGBMRKU-UHFFFAOYSA-N sodium cyanoborohydride Chemical compound [Na+].[B-]C#N BEOOHQFXGBMRKU-UHFFFAOYSA-N 0.000 description 4
• 239000012321 sodium triacetoxyborohydride Substances 0.000 description 4
• UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 4
• RIOQSEWOXXDEQQ-UHFFFAOYSA-N triphenylphosphine Chemical compound C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 RIOQSEWOXXDEQQ-UHFFFAOYSA-N 0.000 description 4
• GTLDTDOJJJZVBW-UHFFFAOYSA-N zinc cyanide Chemical compound [Zn+2].N#[C-].N#[C-] GTLDTDOJJJZVBW-UHFFFAOYSA-N 0.000 description 4
• MRWWWZLJWNIEEJ-UHFFFAOYSA-N 4,4,5,5-tetramethyl-2-propan-2-yloxy-1,3,2-dioxaborolane Chemical compound CC(C)OB1OC(C)(C)C(C)(C)O1 MRWWWZLJWNIEEJ-UHFFFAOYSA-N 0.000 description 3
• ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 3
• WUFADHRATSOXBZ-UHFFFAOYSA-N 8-(2,5-dimethylpyrazol-3-yl)-5-[(5-fluoro-2,3-dihydro-1-benzofuran-4-yl)methylamino]imidazo[1,2-c]pyrimidine-2-carbonitrile Chemical compound CN1N=C(C=C1C=1C=2N(C(=NC=1)NCC1=C(C=CC3=C1CCO3)F)C=C(N=2)C#N)C WUFADHRATSOXBZ-UHFFFAOYSA-N 0.000 description 3
• HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 3
• CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 3
• OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 3
• BDAGIHXWWSANSR-UHFFFAOYSA-N Formic acid Chemical compound OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 3
• 102000011787 Histone Methyltransferases Human genes 0.000 description 3
• 108010036115 Histone Methyltransferases Proteins 0.000 description 3
• 101000833157 Homo sapiens Zinc finger protein AEBP2 Proteins 0.000 description 3
• 239000004472 Lysine Substances 0.000 description 3
• CJLVIMOZCUQEAJ-UHFFFAOYSA-N NC(C)C=1N=C2N(C(=NC=C2C2=CC(=NN2C)C)NCC2=C(C=CC3=C2CCO3)F)C=1 Chemical compound NC(C)C=1N=C2N(C(=NC=C2C2=CC(=NN2C)C)NCC2=C(C=CC3=C2CCO3)F)C=1 CJLVIMOZCUQEAJ-UHFFFAOYSA-N 0.000 description 3
• MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 3
• KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 3
• RWRDLPDLKQPQOW-UHFFFAOYSA-N Pyrrolidine Chemical compound C1CCNC1 RWRDLPDLKQPQOW-UHFFFAOYSA-N 0.000 description 3
• 239000012979 RPMI medium Substances 0.000 description 3
• 239000007868 Raney catalyst Substances 0.000 description 3
• 229910000564 Raney nickel Inorganic materials 0.000 description 3
• 102000007508 Retinoblastoma-Binding Protein 4 Human genes 0.000 description 3
• 108010071034 Retinoblastoma-Binding Protein 4 Proteins 0.000 description 3
• QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 3
• 238000006069 Suzuki reaction reaction Methods 0.000 description 3
• 102100024389 Zinc finger protein AEBP2 Human genes 0.000 description 3
• 125000001931 aliphatic group Chemical group 0.000 description 3
• 230000008901 benefit Effects 0.000 description 3
• 150000001642 boronic acid derivatives Chemical class 0.000 description 3
• GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 3
• 230000003197 catalytic effect Effects 0.000 description 3
• 230000004663 cell proliferation Effects 0.000 description 3
• 238000005119 centrifugation Methods 0.000 description 3
• 239000012043 crude product Substances 0.000 description 3
• 231100000673 dose–response relationship Toxicity 0.000 description 3
• 239000003814 drug Substances 0.000 description 3
• QTTMOCOWZLSYSV-QWAPEVOJSA-M equilin sodium sulfate Chemical compound [Na+].[O-]S(=O)(=O)OC1=CC=C2[C@H]3CC[C@](C)(C(CC4)=O)[C@@H]4C3=CCC2=C1 QTTMOCOWZLSYSV-QWAPEVOJSA-M 0.000 description 3
• RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 3
• 239000011630 iodine Substances 0.000 description 3
• 229910052740 iodine Inorganic materials 0.000 description 3
• 239000012280 lithium aluminium hydride Substances 0.000 description 3
• OKKJLVBELUTLKV-VMNATFBRSA-N methanol-d1 Chemical compound [2H]OC OKKJLVBELUTLKV-VMNATFBRSA-N 0.000 description 3
• 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 3
• PSHKMPUSSFXUIA-UHFFFAOYSA-N n,n-dimethylpyridin-2-amine Chemical compound CN(C)C1=CC=CC=N1 PSHKMPUSSFXUIA-UHFFFAOYSA-N 0.000 description 3
• 230000007935 neutral effect Effects 0.000 description 3
• 230000002018 overexpression Effects 0.000 description 3
• 125000000160 oxazolidinyl group Chemical group 0.000 description 3
• 229920000137 polyphosphoric acid Polymers 0.000 description 3
• 102000004169 proteins and genes Human genes 0.000 description 3
• 239000006228 supernatant Substances 0.000 description 3
• 208000024891 symptom Diseases 0.000 description 3
• FPJOPPJXKZEKBE-UHFFFAOYSA-N tert-butyl N-[(5-fluoro-2,3-dihydro-1-benzofuran-4-yl)methyl]carbamate Chemical compound FC=1C=CC2=C(CCO2)C=1CNC(OC(C)(C)C)=O FPJOPPJXKZEKBE-UHFFFAOYSA-N 0.000 description 3
• 238000012360 testing method Methods 0.000 description 3
• 125000004568 thiomorpholinyl group Chemical group 0.000 description 3
• 239000011534 wash buffer Substances 0.000 description 3
• 239000011701 zinc Substances 0.000 description 3
• VKHBVOASPGGBFX-UHFFFAOYSA-N (4-bromo-3-methylphenyl) thiocyanate Chemical compound BrC1=C(C=C(C=C1)SC#N)C VKHBVOASPGGBFX-UHFFFAOYSA-N 0.000 description 2
• JWUSUGNPYWQHHT-UHFFFAOYSA-N (5-fluoro-1,3-benzodioxol-4-yl)methanamine Chemical compound C1=C(F)C(CN)=C2OCOC2=C1 JWUSUGNPYWQHHT-UHFFFAOYSA-N 0.000 description 2
• RJQJPUJXDMPZHE-UHFFFAOYSA-N (5-fluoro-1-benzothiophen-4-yl)methanamine Chemical compound FC=1C=CC2=C(C=CS2)C=1CN RJQJPUJXDMPZHE-UHFFFAOYSA-N 0.000 description 2
• 125000004169 (C1-C6) alkyl group Chemical group 0.000 description 2
• HWAXLMKQPVZTBY-UHFFFAOYSA-N 1-(4-bromophenyl)-4-chlorobutan-1-ol Chemical compound ClCCCC(O)C1=CC=C(Br)C=C1 HWAXLMKQPVZTBY-UHFFFAOYSA-N 0.000 description 2
• WHSLCLOMSJQONW-UHFFFAOYSA-N 1-(5-bromo-6-methylpyridin-2-yl)-4-methylpiperazine Chemical compound C1CN(C)CCN1C1=CC=C(Br)C(C)=N1 WHSLCLOMSJQONW-UHFFFAOYSA-N 0.000 description 2
• QGCHPDGYVYGLTE-UHFFFAOYSA-N 1-[1-(4-bromophenyl)ethyl]pyrrolidine Chemical compound C=1C=C(Br)C=CC=1C(C)N1CCCC1 QGCHPDGYVYGLTE-UHFFFAOYSA-N 0.000 description 2
• IANQTJSKSUMEQM-UHFFFAOYSA-N 1-benzofuran Chemical group C1=CC=C2OC=CC2=C1 IANQTJSKSUMEQM-UHFFFAOYSA-N 0.000 description 2
• VCQONKRSTAUGEP-UHFFFAOYSA-N 1-benzofuran-4-carbonitrile Chemical compound N#CC1=CC=CC2=C1C=CO2 VCQONKRSTAUGEP-UHFFFAOYSA-N 0.000 description 2
• DOGMHMRYOCKWBI-UHFFFAOYSA-N 1-bromo-2-methyl-4-(trifluoromethylsulfanyl)benzene Chemical compound CC1=C(Br)C=CC(SC(F)(F)F)=C1 DOGMHMRYOCKWBI-UHFFFAOYSA-N 0.000 description 2
• OSRFQHIAYGVFCW-UHFFFAOYSA-N 1-bromo-2-methyl-4-(trifluoromethylsulfonyl)benzene Chemical compound CC1=CC(S(=O)(=O)C(F)(F)F)=CC=C1Br OSRFQHIAYGVFCW-UHFFFAOYSA-N 0.000 description 2
• HAHBIJBMSCJNII-UHFFFAOYSA-N 1-bromo-2-methyl-4-methylsulfanylbenzene Chemical compound CSC1=CC=C(Br)C(C)=C1 HAHBIJBMSCJNII-UHFFFAOYSA-N 0.000 description 2
• PGHRWRDJUMHHHX-UHFFFAOYSA-N 1-bromo-2-methyl-4-methylsulfonylbenzene Chemical compound CC1=CC(S(C)(=O)=O)=CC=C1Br PGHRWRDJUMHHHX-UHFFFAOYSA-N 0.000 description 2
• BXNLYIJBCFCSBQ-UHFFFAOYSA-N 1-bromo-3-(2,2-diethoxyethoxy)benzene Chemical compound CCOC(OCC)COC1=CC=CC(Br)=C1 BXNLYIJBCFCSBQ-UHFFFAOYSA-N 0.000 description 2
• WBJRWCXJMRZDPA-UHFFFAOYSA-N 1-bromo-4-diethoxyphosphorylbenzene Chemical compound CCOP(=O)(OCC)C1=CC=C(Br)C=C1 WBJRWCXJMRZDPA-UHFFFAOYSA-N 0.000 description 2
• BVQVLAIMHVDZEL-UHFFFAOYSA-N 1-phenyl-1,2-propanedione Chemical compound CC(=O)C(=O)C1=CC=CC=C1 BVQVLAIMHVDZEL-UHFFFAOYSA-N 0.000 description 2
• CHDSHBWEGSCEDX-UHFFFAOYSA-N 2,3-dihydro-1-benzofuran-4-carboxylic acid Chemical compound OC(=O)C1=CC=CC2=C1CCO2 CHDSHBWEGSCEDX-UHFFFAOYSA-N 0.000 description 2
• UWUKAWBQXOWSMP-UHFFFAOYSA-N 2,5-dibromo-3-fluoro-4-methylpyridine Chemical compound BrC1=NC=C(C(=C1F)C)Br UWUKAWBQXOWSMP-UHFFFAOYSA-N 0.000 description 2
• WHJLISQDROHCSH-UHFFFAOYSA-N 2-(4-bromo-3-methylphenyl)-1,3-dioxolane Chemical compound C1=C(Br)C(C)=CC(C2OCCO2)=C1 WHJLISQDROHCSH-UHFFFAOYSA-N 0.000 description 2
• RIEICTJOEICJJT-UHFFFAOYSA-N 2-(4-bromophenyl)-1-methylpyrrolidine Chemical compound CN1CCCC1C1=CC=C(Br)C=C1 RIEICTJOEICJJT-UHFFFAOYSA-N 0.000 description 2
• RWCMKTSVOYKLQY-UHFFFAOYSA-N 2-(4-bromophenyl)-n,n-dimethylethanamine Chemical compound CN(C)CCC1=CC=C(Br)C=C1 RWCMKTSVOYKLQY-UHFFFAOYSA-N 0.000 description 2
• OUJWSBTVHIGHIS-UHFFFAOYSA-N 2-(4-bromophenyl)oxolane Chemical compound C1=CC(Br)=CC=C1C1OCCC1 OUJWSBTVHIGHIS-UHFFFAOYSA-N 0.000 description 2
• HIJZBROSVFKSCP-UHFFFAOYSA-N 2-(4-bromophenyl)pyrrolidine Chemical compound C1=CC(Br)=CC=C1C1NCCC1 HIJZBROSVFKSCP-UHFFFAOYSA-N 0.000 description 2
• XXXMURLCTMDGRI-UHFFFAOYSA-N 2-bromo-4-(2,2-diethoxyethylsulfanyl)-1-fluorobenzene Chemical compound CCOC(OCC)CSC1=CC=C(F)C(Br)=C1 XXXMURLCTMDGRI-UHFFFAOYSA-N 0.000 description 2
• OOOLAZSWCDZAFE-UHFFFAOYSA-N 2-cyclopropyl-6-methyl-1h-pyrimidin-4-one Chemical compound N1C(C)=CC(=O)N=C1C1CC1 OOOLAZSWCDZAFE-UHFFFAOYSA-N 0.000 description 2
• OOSYIPBHQFCHRS-UHFFFAOYSA-N 3,4-dihydro-2h-chromen-5-ylmethanamine Chemical compound O1CCCC2=C1C=CC=C2CN OOSYIPBHQFCHRS-UHFFFAOYSA-N 0.000 description 2
• UNRKERPUVDJBJU-UHFFFAOYSA-N 3,4-dihydro-2h-chromene-5-carbonitrile Chemical compound O1CCCC2=C1C=CC=C2C#N UNRKERPUVDJBJU-UHFFFAOYSA-N 0.000 description 2
• GNUDAJTUCJEBEI-UHFFFAOYSA-N 3,5-dimethyl-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1h-pyrazole Chemical compound CC1=NNC(C)=C1B1OC(C)(C)C(C)(C)O1 GNUDAJTUCJEBEI-UHFFFAOYSA-N 0.000 description 2
• XNHDJBJSICAZMR-UHFFFAOYSA-N 3-bromo-1-phenylpropane-1,2-dione Chemical compound BrCC(=O)C(=O)C1=CC=CC=C1 XNHDJBJSICAZMR-UHFFFAOYSA-N 0.000 description 2
• CPRDEBQLVGNTNJ-UHFFFAOYSA-N 3-bromo-2-(3-hydroxypropyl)phenol Chemical compound OCCCC1=C(O)C=CC=C1Br CPRDEBQLVGNTNJ-UHFFFAOYSA-N 0.000 description 2
• OSNRLWHLHYCXGT-UHFFFAOYSA-N 3-bromo-2-(3-iodopropyl)phenol Chemical compound BrC=1C(=C(C=CC=1)O)CCCI OSNRLWHLHYCXGT-UHFFFAOYSA-N 0.000 description 2
• QWTULQLVGNZMLF-UHFFFAOYSA-N 3-bromo-4-fluorophenol Chemical compound OC1=CC=C(F)C(Br)=C1 QWTULQLVGNZMLF-UHFFFAOYSA-N 0.000 description 2
• NHQDETIJWKXCTC-UHFFFAOYSA-N 3-chloroperbenzoic acid Chemical compound OOC(=O)C1=CC=CC(Cl)=C1 NHQDETIJWKXCTC-UHFFFAOYSA-N 0.000 description 2
• YFKGZOJEQUDHAD-UHFFFAOYSA-N 4-bromo-1-benzofuran Chemical compound BrC1=CC=CC2=C1C=CO2 YFKGZOJEQUDHAD-UHFFFAOYSA-N 0.000 description 2
• YDZUJZNFBSMIAA-UHFFFAOYSA-N 4-bromo-3-chloro-n,n-dimethylbenzamide Chemical compound CN(C)C(=O)C1=CC=C(Br)C(Cl)=C1 YDZUJZNFBSMIAA-UHFFFAOYSA-N 0.000 description 2
• YBXGUHGVNUFFJU-UHFFFAOYSA-N 4-bromo-3-methylbenzaldehyde Chemical compound CC1=CC(C=O)=CC=C1Br YBXGUHGVNUFFJU-UHFFFAOYSA-N 0.000 description 2
• UTTXDQNAXUGSDF-UHFFFAOYSA-N 4-bromo-5-fluoro-1-benzothiophene Chemical compound FC1=CC=C2SC=CC2=C1Br UTTXDQNAXUGSDF-UHFFFAOYSA-N 0.000 description 2
• STYQHICBPYRHQK-UHFFFAOYSA-N 4-bromobenzenesulfonamide Chemical compound NS(=O)(=O)C1=CC=C(Br)C=C1 STYQHICBPYRHQK-UHFFFAOYSA-N 0.000 description 2
• JXIFEBCWAJUBPN-UHFFFAOYSA-N 4-chloro-2-methylpyridazin-3-one Chemical compound CN1N=CC=C(Cl)C1=O JXIFEBCWAJUBPN-UHFFFAOYSA-N 0.000 description 2
• ICGLPKIVTVWCFT-UHFFFAOYSA-N 4-methylbenzenesulfonohydrazide Chemical compound CC1=CC=C(S(=O)(=O)NN)C=C1 ICGLPKIVTVWCFT-UHFFFAOYSA-N 0.000 description 2
• OTNCKNIATISMHD-UHFFFAOYSA-N 5-bromo-2-(2-methoxyethoxy)pyrimidine Chemical compound COCCOC1=NC=C(Br)C=N1 OTNCKNIATISMHD-UHFFFAOYSA-N 0.000 description 2
• ABPPZHDAUANIRB-UHFFFAOYSA-N 5-bromo-2-[(dimethylamino)methyl]benzonitrile Chemical compound CN(C)Cc1ccc(Br)cc1C#N ABPPZHDAUANIRB-UHFFFAOYSA-N 0.000 description 2
• IIALSLVGUGOODS-UHFFFAOYSA-N 5-bromo-2-chloro-4-methylpyrimidine Chemical compound CC1=NC(Cl)=NC=C1Br IIALSLVGUGOODS-UHFFFAOYSA-N 0.000 description 2
• IKWKEICYVKOUNC-UHFFFAOYSA-N 5-bromo-2-cyclopropyl-4-methylpyrimidine Chemical compound C1=C(Br)C(C)=NC(C2CC2)=N1 IKWKEICYVKOUNC-UHFFFAOYSA-N 0.000 description 2
• DPYHKOWANQWWOY-UHFFFAOYSA-N 5-bromo-2-cyclopropyl-6-methyl-1h-pyrimidin-4-one Chemical compound O=C1C(Br)=C(C)NC(C2CC2)=N1 DPYHKOWANQWWOY-UHFFFAOYSA-N 0.000 description 2
• NQYSLCWSLFWCEX-UHFFFAOYSA-N 5-bromo-2-methoxy-4-methylpyrimidine Chemical compound COC1=NC=C(Br)C(C)=N1 NQYSLCWSLFWCEX-UHFFFAOYSA-N 0.000 description 2
• LHCOEOUYRDDIJP-UHFFFAOYSA-N 5-bromo-3,4-dihydro-2h-chromene Chemical compound O1CCCC2=C1C=CC=C2Br LHCOEOUYRDDIJP-UHFFFAOYSA-N 0.000 description 2
• NOTVADUCMHIWMH-UHFFFAOYSA-N 5-bromo-3-fluoro-4-methylpyridine-2-carbaldehyde Chemical compound BrC=1C(=C(C(=NC=1)C=O)F)C NOTVADUCMHIWMH-UHFFFAOYSA-N 0.000 description 2
• JKWNULKFDXPCMP-UHFFFAOYSA-N 5-bromo-4-chloro-2-cyclopropyl-6-methylpyrimidine Chemical compound ClC1=C(Br)C(C)=NC(C2CC2)=N1 JKWNULKFDXPCMP-UHFFFAOYSA-N 0.000 description 2
• VAWAMISTAORKHR-UHFFFAOYSA-N 5-bromo-4-methyl-2-propan-2-yloxypyrimidine Chemical compound BrC=1C(=NC(=NC=1)OC(C)C)C VAWAMISTAORKHR-UHFFFAOYSA-N 0.000 description 2
• FLESSTROMZTVIB-UHFFFAOYSA-N 5-chloro-2,3-dihydro-1-benzofuran-4-carboxamide Chemical compound ClC1=CC=C2C(CCO2)=C1C(=O)N FLESSTROMZTVIB-UHFFFAOYSA-N 0.000 description 2
• PPNDECOBTADBFJ-UHFFFAOYSA-N 5-fluoro-1,3-benzodioxole-4-carbaldehyde Chemical compound FC1=CC=C2OCOC2=C1C=O PPNDECOBTADBFJ-UHFFFAOYSA-N 0.000 description 2
• WSQKGPKIUYBEFQ-UHFFFAOYSA-N 5-fluoro-1-benzofuran-4-carboxamide Chemical compound FC1=CC=C2C(C=CO2)=C1C(=O)N WSQKGPKIUYBEFQ-UHFFFAOYSA-N 0.000 description 2
• AUSWCXUVANQJNF-UHFFFAOYSA-N 5-fluoro-1-benzothiophene-4-carbonitrile Chemical compound Fc1ccc2sccc2c1C#N AUSWCXUVANQJNF-UHFFFAOYSA-N 0.000 description 2
• YAZMJSJWXYPOHX-UHFFFAOYSA-N 5-fluoro-2,3-dihydro-1-benzofuran-4-carboxamide Chemical compound FC1=CC=C2C(CCO2)=C1C(=O)N YAZMJSJWXYPOHX-UHFFFAOYSA-N 0.000 description 2
• PNZDKWGVPHBMRZ-UHFFFAOYSA-N 6-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-3,4-dihydro-2h-isoquinolin-1-one Chemical compound O1C(C)(C)C(C)(C)OB1C1=CC=C(C(=O)NCC2)C2=C1 PNZDKWGVPHBMRZ-UHFFFAOYSA-N 0.000 description 2
• URDGCPQHZSDBRG-UHFFFAOYSA-N 6-bromo-1,2,3,4-tetrahydroisoquinoline Chemical compound C1NCCC2=CC(Br)=CC=C21 URDGCPQHZSDBRG-UHFFFAOYSA-N 0.000 description 2
• XBWCPPFVDGLVMN-UHFFFAOYSA-N 6-bromo-2-methyl-3,4-dihydro-1h-isoquinoline Chemical compound BrC1=CC=C2CN(C)CCC2=C1 XBWCPPFVDGLVMN-UHFFFAOYSA-N 0.000 description 2
• QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 2
• 108091003079 Bovine Serum Albumin Proteins 0.000 description 2
• KAVDMQDBSGSBLO-VOTSOKGWSA-N BrC1=C(C(=CC=C1)O)/C=C/C(=O)OCC Chemical compound BrC1=C(C(=CC=C1)O)/C=C/C(=O)OCC KAVDMQDBSGSBLO-VOTSOKGWSA-N 0.000 description 2
• JEVUEARETKSBTR-UHFFFAOYSA-N BrC=1C(=C(C(=NC=1)C1OCCO1)F)C Chemical compound BrC=1C(=C(C(=NC=1)C1OCCO1)F)C JEVUEARETKSBTR-UHFFFAOYSA-N 0.000 description 2
• MVVCJDVLLNSPII-UHFFFAOYSA-N BrC=1C(=CC(=NC=1)C1OCCO1)C Chemical compound BrC=1C(=CC(=NC=1)C1OCCO1)C MVVCJDVLLNSPII-UHFFFAOYSA-N 0.000 description 2
• OJMUYNZDWNGNLW-UHFFFAOYSA-N BrC=1C=2N(C(=NC=1)Cl)C=C(N=2)C(=O)C1=CC=CC=C1 Chemical compound BrC=1C=2N(C(=NC=1)Cl)C=C(N=2)C(=O)C1=CC=CC=C1 OJMUYNZDWNGNLW-UHFFFAOYSA-N 0.000 description 2
• VKDXLWFHBCHPNW-UHFFFAOYSA-N BrC=1C=2N(C(=NC=1)NCC1=C(C=CC3=C1CCO3)F)C=C(N=2)C(C1CC1)NC(OC(C)(C)C)=O Chemical compound BrC=1C=2N(C(=NC=1)NCC1=C(C=CC3=C1CCO3)F)C=C(N=2)C(C1CC1)NC(OC(C)(C)C)=O VKDXLWFHBCHPNW-UHFFFAOYSA-N 0.000 description 2
• WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 2
• CUJSVMBPFAMUHJ-UHFFFAOYSA-N C(C)(C)(C)OC(=O)NC(C)C=1N=C2N(C(=NC=C2C2=CC(=NN2C)C(=O)O)NCC2=C(C=CC3=C2CCO3)F)C=1 Chemical compound C(C)(C)(C)OC(=O)NC(C)C=1N=C2N(C(=NC=C2C2=CC(=NN2C)C(=O)O)NCC2=C(C=CC3=C2CCO3)F)C=1 CUJSVMBPFAMUHJ-UHFFFAOYSA-N 0.000 description 2
• BITDPUUKYCLNHM-UHFFFAOYSA-N C(C1=CC=CC=C1)(=O)C=1N=C2N(C(NC=C2Br)=O)C=1 Chemical compound C(C1=CC=CC=C1)(=O)C=1N=C2N(C(NC=C2Br)=O)C=1 BITDPUUKYCLNHM-UHFFFAOYSA-N 0.000 description 2
• CRJCIVHFCBTLFF-UHFFFAOYSA-N C1(CC1)C(C=1N=C2N(C(=NC=C2C2=CC(=NN2C)C)NCC2=C(C=CC3=C2CCO3)F)C=1)NC(OC(C)(C)C)=O Chemical compound C1(CC1)C(C=1N=C2N(C(=NC=C2C2=CC(=NN2C)C)NCC2=C(C=CC3=C2CCO3)F)C=1)NC(OC(C)(C)C)=O CRJCIVHFCBTLFF-UHFFFAOYSA-N 0.000 description 2
• SJNXIPYOADQGQY-UHFFFAOYSA-N C1(CCC1)NCC=1N=C2N(C(=NC=C2C2=CC(=NN2C)C)NCC2=C(C=CC3=C2CCO3)F)C=1 Chemical compound C1(CCC1)NCC=1N=C2N(C(=NC=C2C2=CC(=NN2C)C)NCC2=C(C=CC3=C2CCO3)F)C=1 SJNXIPYOADQGQY-UHFFFAOYSA-N 0.000 description 2
• FNHUVEMKBOXZIE-UHFFFAOYSA-N CC1=C(C=CC(=C1)S(C)(=O)=O)C1=CN=C(NCC2=C(F)C=CC3=C2CCO3)N2C=C(N=C12)C#N Chemical compound CC1=C(C=CC(=C1)S(C)(=O)=O)C1=CN=C(NCC2=C(F)C=CC3=C2CCO3)N2C=C(N=C12)C#N FNHUVEMKBOXZIE-UHFFFAOYSA-N 0.000 description 2
• VJONJTQNAWDLNJ-UHFFFAOYSA-N CN(C)Cc1ccc(Br)c(C)c1 Chemical compound CN(C)Cc1ccc(Br)c(C)c1 VJONJTQNAWDLNJ-UHFFFAOYSA-N 0.000 description 2
• NKBQITNOABLNIP-UHFFFAOYSA-N CN1N=C(C=C1C=1C=2N(C(=NC=1)N(C(OC(C)(C)C)=O)CC1=C(C=CC3=C1CCO3)F)C=C(N=2)C(C(F)(F)F)O)C Chemical compound CN1N=C(C=C1C=1C=2N(C(=NC=1)N(C(OC(C)(C)C)=O)CC1=C(C=CC3=C1CCO3)F)C=C(N=2)C(C(F)(F)F)O)C NKBQITNOABLNIP-UHFFFAOYSA-N 0.000 description 2
• GOXQESOLANWHQU-UHFFFAOYSA-N CN1N=C(C=C1C=1C=2N(C(=NC=1)N(C(OC(C)(C)C)=O)CC1=C(C=CC3=C1CCO3)F)C=C(N=2)C=O)C Chemical compound CN1N=C(C=C1C=1C=2N(C(=NC=1)N(C(OC(C)(C)C)=O)CC1=C(C=CC3=C1CCO3)F)C=C(N=2)C=O)C GOXQESOLANWHQU-UHFFFAOYSA-N 0.000 description 2
• PDLKHANHITYUES-UHFFFAOYSA-N CN1N=C(C=C1C=1C=2N(C(=NC=1)N(C(OC(C)(C)C)=O)CC1=C(C=CC3=C1CCO3)F)C=C(N=2)CO)C Chemical compound CN1N=C(C=C1C=1C=2N(C(=NC=1)N(C(OC(C)(C)C)=O)CC1=C(C=CC3=C1CCO3)F)C=C(N=2)CO)C PDLKHANHITYUES-UHFFFAOYSA-N 0.000 description 2
• LGDSEZGVZTVERI-UHFFFAOYSA-N CN1N=C(C=C1C=1C=2N(C(=NC=1)N(C(OC(C)(C)C)=O)CC1=C(C=CC3=C1CCO3)F)C=C(N=2)COC)C Chemical compound CN1N=C(C=C1C=1C=2N(C(=NC=1)N(C(OC(C)(C)C)=O)CC1=C(C=CC3=C1CCO3)F)C=C(N=2)COC)C LGDSEZGVZTVERI-UHFFFAOYSA-N 0.000 description 2
• ILPLDKIYLHNCEZ-UHFFFAOYSA-N CN1N=C(C=C1C=1C=2N(C(=NC=1)NCC1=C(C=CC3=C1CCO3)F)C=C(N=2)C(=O)C1=CC=CC=C1)C Chemical compound CN1N=C(C=C1C=1C=2N(C(=NC=1)NCC1=C(C=CC3=C1CCO3)F)C=C(N=2)C(=O)C1=CC=CC=C1)C ILPLDKIYLHNCEZ-UHFFFAOYSA-N 0.000 description 2
• YTWCPIICULYLNL-UHFFFAOYSA-N CN1N=C(C=C1C=1C=2N(C(=NC=1)NCC1=C(C=CC3=C1CCO3)F)C=C(N=2)C(=O)NN)C Chemical compound CN1N=C(C=C1C=1C=2N(C(=NC=1)NCC1=C(C=CC3=C1CCO3)F)C=C(N=2)C(=O)NN)C YTWCPIICULYLNL-UHFFFAOYSA-N 0.000 description 2
• BSTUAFFRZLRUMR-UHFFFAOYSA-N CN1N=C(C=C1C=1C=2N(C(=NC=1)NCC1=C(C=CC3=C1CCO3)F)C=C(N=2)C(C)NC(OC(C)(C)C)=O)C Chemical compound CN1N=C(C=C1C=1C=2N(C(=NC=1)NCC1=C(C=CC3=C1CCO3)F)C=C(N=2)C(C)NC(OC(C)(C)C)=O)C BSTUAFFRZLRUMR-UHFFFAOYSA-N 0.000 description 2
• DZDBSOHOXMYOPS-UHFFFAOYSA-N CN1N=C(C=C1C=1C=2N(C(=NC=1)NCC1=C(C=CC3=C1CCO3)F)C=C(N=2)C(C)O)C Chemical compound CN1N=C(C=C1C=1C=2N(C(=NC=1)NCC1=C(C=CC3=C1CCO3)F)C=C(N=2)C(C)O)C DZDBSOHOXMYOPS-UHFFFAOYSA-N 0.000 description 2
• FRMGONKFGHGEDM-UHFFFAOYSA-N CN1N=C(C=C1C=1C=2N(C(=NC=1)NCC1=C(C=CC3=C1CCO3)F)C=C(N=2)C(O)C1=CC=CC=C1)C Chemical compound CN1N=C(C=C1C=1C=2N(C(=NC=1)NCC1=C(C=CC3=C1CCO3)F)C=C(N=2)C(O)C1=CC=CC=C1)C FRMGONKFGHGEDM-UHFFFAOYSA-N 0.000 description 2
• FIABGGUWUBQLIX-UHFFFAOYSA-N CN1N=C(C=C1C=1C=2N(C(=NC=1)NCC1=C(C=CC3=C1CCO3)F)C=C(N=2)C1=CN=CO1)C Chemical compound CN1N=C(C=C1C=1C=2N(C(=NC=1)NCC1=C(C=CC3=C1CCO3)F)C=C(N=2)C1=CN=CO1)C FIABGGUWUBQLIX-UHFFFAOYSA-N 0.000 description 2
• ARVNNNAHZHBLFN-UHFFFAOYSA-N CN1N=C(C=C1C=1C=2N(C(=NC=1)NCC1=C(C=CC3=C1CCO3)F)C=C(N=2)C=1N=NNN=1)C Chemical compound CN1N=C(C=C1C=1C=2N(C(=NC=1)NCC1=C(C=CC3=C1CCO3)F)C=C(N=2)C=1N=NNN=1)C ARVNNNAHZHBLFN-UHFFFAOYSA-N 0.000 description 2
• QSCBENZELMFGOL-UHFFFAOYSA-N CN1N=C(C=C1C=1C=2N(C(=NC=1)NCC1=C(C=CC3=C1CCO3)F)C=C(N=2)C=1OC=NN=1)C Chemical compound CN1N=C(C=C1C=1C=2N(C(=NC=1)NCC1=C(C=CC3=C1CCO3)F)C=C(N=2)C=1OC=NN=1)C QSCBENZELMFGOL-UHFFFAOYSA-N 0.000 description 2
• RRIIZQBJUAHTOG-UHFFFAOYSA-N CN1N=C(C=C1C=1C=2N(C(=NC=1)NCC1=C(C=CC3=C1CCO3)F)C=C(N=2)CN(C)C)C Chemical compound CN1N=C(C=C1C=1C=2N(C(=NC=1)NCC1=C(C=CC3=C1CCO3)F)C=C(N=2)CN(C)C)C RRIIZQBJUAHTOG-UHFFFAOYSA-N 0.000 description 2
• TVRKPPMJTOJUHI-UHFFFAOYSA-N CN1N=C(C=C1C=1C=2N(C(=NC=1)NCC1=C(C=CC3=C1CCO3)F)C=C(N=2)CNC)C Chemical compound CN1N=C(C=C1C=1C=2N(C(=NC=1)NCC1=C(C=CC3=C1CCO3)F)C=C(N=2)CNC)C TVRKPPMJTOJUHI-UHFFFAOYSA-N 0.000 description 2
• ZTWAOTIKFADHMT-UHFFFAOYSA-N CN1N=C(C=C1C=1C=2N(C(=NC=1)NCC1=C(C=CC3=C1CCO3)F)C=C(N=2)COC)C Chemical compound CN1N=C(C=C1C=1C=2N(C(=NC=1)NCC1=C(C=CC3=C1CCO3)F)C=C(N=2)COC)C ZTWAOTIKFADHMT-UHFFFAOYSA-N 0.000 description 2
• FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 2
• 238000002965 ELISA Methods 0.000 description 2
• NHOWYGKCMRPLSS-UHFFFAOYSA-N FC=1C=CC2=C(C=CO2)C=1CN Chemical compound FC=1C=CC2=C(C=CO2)C=1CN NHOWYGKCMRPLSS-UHFFFAOYSA-N 0.000 description 2
• XMYKPHZTXYPKLL-UHFFFAOYSA-N FC=1C=CC2=C(CCO2)C=1CNC1=NC=C(C=2N1C=C(N=2)C(=O)OCC)C1=C(C=C(C=C1)S(=O)(=O)C)C Chemical compound FC=1C=CC2=C(CCO2)C=1CNC1=NC=C(C=2N1C=C(N=2)C(=O)OCC)C1=C(C=C(C=C1)S(=O)(=O)C)C XMYKPHZTXYPKLL-UHFFFAOYSA-N 0.000 description 2
• RJGKNQMGDVLEDD-UHFFFAOYSA-N FC=1C=CC2=C(CCO2)C=1CNC1=NC=C(C=2N1C=C(N=2)C(C)NC(OC(C)(C)C)=O)C1=C(C=C(C=C1)S(=O)(=O)C)C Chemical compound FC=1C=CC2=C(CCO2)C=1CNC1=NC=C(C=2N1C=C(N=2)C(C)NC(OC(C)(C)C)=O)C1=C(C=C(C=C1)S(=O)(=O)C)C RJGKNQMGDVLEDD-UHFFFAOYSA-N 0.000 description 2
• DULHIKBIAKGJGD-UHFFFAOYSA-N FC=1C=CC2=C(CCO2)C=1CNC1=NC=C(C=2N1C=C(N=2)CO)C1=C(C=C(C=C1)S(=O)(=O)C)C Chemical compound FC=1C=CC2=C(CCO2)C=1CNC1=NC=C(C=2N1C=C(N=2)CO)C1=C(C=C(C=C1)S(=O)(=O)C)C DULHIKBIAKGJGD-UHFFFAOYSA-N 0.000 description 2
• MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 2
• WTDHULULXKLSOZ-UHFFFAOYSA-N Hydroxylamine hydrochloride Chemical compound Cl.ON WTDHULULXKLSOZ-UHFFFAOYSA-N 0.000 description 2
• KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
• BAVYZALUXZFZLV-UHFFFAOYSA-N Methylamine Chemical compound NC BAVYZALUXZFZLV-UHFFFAOYSA-N 0.000 description 2
• OAZSOLHRDDXVLM-UHFFFAOYSA-N N'-(5-bromo-2-cyclopropyl-6-methylpyrimidin-4-yl)-4-methylbenzenesulfonohydrazide Chemical compound BrC=1C(=NC(=NC=1C)C1CC1)NNS(=O)(=O)C1=CC=C(C=C1)C OAZSOLHRDDXVLM-UHFFFAOYSA-N 0.000 description 2
• KYQZNLQWOSTKFE-UHFFFAOYSA-N N-[(5-fluoro-1,3-benzodioxol-4-yl)methylidene]hydroxylamine Chemical compound ON=CC1=C(F)C=CC2=C1OCO2 KYQZNLQWOSTKFE-UHFFFAOYSA-N 0.000 description 2
• YMUOAUVOALDIJI-UHFFFAOYSA-N N1(CCC1)CC=1N=C2N(C(=NC=C2C2=CC=NN2C)NCC2=C(C=CC3=C2CCO3)F)C=1 Chemical compound N1(CCC1)CC=1N=C2N(C(=NC=C2C2=CC=NN2C)NCC2=C(C=CC3=C2CCO3)F)C=1 YMUOAUVOALDIJI-UHFFFAOYSA-N 0.000 description 2
• YMBNZMNACSIZFR-UHFFFAOYSA-N NC(C(F)(F)F)C=1N=C2N(C(=NC=C2C2=CC(=NN2C)C)N(C(OC(C)(C)C)=O)CC2=C(C=CC3=C2CCO3)F)C=1 Chemical compound NC(C(F)(F)F)C=1N=C2N(C(=NC=C2C2=CC(=NN2C)C)N(C(OC(C)(C)C)=O)CC2=C(C=CC3=C2CCO3)F)C=1 YMBNZMNACSIZFR-UHFFFAOYSA-N 0.000 description 2
• SHHKMZXKPTUBAY-UHFFFAOYSA-N NC(C(F)(F)F)C=1N=C2N(C(=NC=C2C2=CC(=NN2C)C)NCC2=C(C=CC3=C2CCO3)F)C=1 Chemical compound NC(C(F)(F)F)C=1N=C2N(C(=NC=C2C2=CC(=NN2C)C)NCC2=C(C=CC3=C2CCO3)F)C=1 SHHKMZXKPTUBAY-UHFFFAOYSA-N 0.000 description 2
• NSWXKBWDKICNLX-UHFFFAOYSA-N NC(C)C=1N=C2N(C(=NC=C2Br)NCC2=C(C=CC3=C2CCO3)F)C=1 Chemical compound NC(C)C=1N=C2N(C(=NC=C2Br)NCC2=C(C=CC3=C2CCO3)F)C=1 NSWXKBWDKICNLX-UHFFFAOYSA-N 0.000 description 2
• MYZIPYGLTAKQIH-UHFFFAOYSA-N NC(C)C=1N=C2N(C(=NC=C2C2=C(C=C(C=C2)S(=O)(=O)C)C)NCC2=C(C=CC3=C2CCO3)F)C=1 Chemical compound NC(C)C=1N=C2N(C(=NC=C2C2=C(C=C(C=C2)S(=O)(=O)C)C)NCC2=C(C=CC3=C2CCO3)F)C=1 MYZIPYGLTAKQIH-UHFFFAOYSA-N 0.000 description 2
• AQSRNORBYLLODU-UHFFFAOYSA-N NC(C)C=1N=C2N(C(=NC=C2C2=CC(=NN2C)C#N)NCC2=C(C=CC3=C2CCO3)F)C=1 Chemical compound NC(C)C=1N=C2N(C(=NC=C2C2=CC(=NN2C)C#N)NCC2=C(C=CC3=C2CCO3)F)C=1 AQSRNORBYLLODU-UHFFFAOYSA-N 0.000 description 2
• YRMCKIIDCKHUAG-UHFFFAOYSA-N NC(C=1N=C2N(C(=NC=C2Br)NCC2=C(C=CC3=C2CCO3)F)C=1)C1CC1 Chemical compound NC(C=1N=C2N(C(=NC=C2Br)NCC2=C(C=CC3=C2CCO3)F)C=1)C1CC1 YRMCKIIDCKHUAG-UHFFFAOYSA-N 0.000 description 2
• KEXZENJSPDNQRT-UHFFFAOYSA-N NC(C=1N=C2N(C(=NC=C2C2=CC(=NN2C)C)NCC2=C(C=CC3=C2CCO3)F)C=1)C1CC1 Chemical compound NC(C=1N=C2N(C(=NC=C2C2=CC(=NN2C)C)NCC2=C(C=CC3=C2CCO3)F)C=1)C1CC1 KEXZENJSPDNQRT-UHFFFAOYSA-N 0.000 description 2
• URLDJDPENVUSJA-UHFFFAOYSA-N NCc1c2CCOc2ccc1Cl Chemical compound NCc1c2CCOc2ccc1Cl URLDJDPENVUSJA-UHFFFAOYSA-N 0.000 description 2
• DHFHFOOEHRVPAN-UHFFFAOYSA-N OC(=O)c1c2CCOc2ccc1Cl Chemical compound OC(=O)c1c2CCOc2ccc1Cl DHFHFOOEHRVPAN-UHFFFAOYSA-N 0.000 description 2
• 206010033128 Ovarian cancer Diseases 0.000 description 2
• 229930040373 Paraformaldehyde Natural products 0.000 description 2
• 229930182555 Penicillin Natural products 0.000 description 2
• JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 2
• NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
• MEFKEPWMEQBLKI-AIRLBKTGSA-N S-adenosyl-L-methioninate Chemical compound O[C@@H]1[C@H](O)[C@@H](C[S+](CC[C@H](N)C([O-])=O)C)O[C@H]1N1C2=NC=NC(N)=C2N=C1 MEFKEPWMEQBLKI-AIRLBKTGSA-N 0.000 description 2
• 102000051614 SET domains Human genes 0.000 description 2
• 108700039010 SET domains Proteins 0.000 description 2
• KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 2
• PXIPVTKHYLBLMZ-UHFFFAOYSA-N Sodium azide Chemical compound [Na+].[N-]=[N+]=[N-] PXIPVTKHYLBLMZ-UHFFFAOYSA-N 0.000 description 2
• XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 2
• 230000001594 aberrant effect Effects 0.000 description 2
• 239000002253 acid Substances 0.000 description 2
• 229960001570 ademetionine Drugs 0.000 description 2
• 125000004450 alkenylene group Chemical group 0.000 description 2
• 125000004419 alkynylene group Chemical group 0.000 description 2
• BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 2
• PNEYBMLMFCGWSK-UHFFFAOYSA-N aluminium oxide Inorganic materials [O-2].[O-2].[O-2].[Al+3].[Al+3] PNEYBMLMFCGWSK-UHFFFAOYSA-N 0.000 description 2
• 229910021529 ammonia Inorganic materials 0.000 description 2
• 235000012538 ammonium bicarbonate Nutrition 0.000 description 2
• 125000000732 arylene group Chemical group 0.000 description 2
• 235000010323 ascorbic acid Nutrition 0.000 description 2
• 239000011668 ascorbic acid Substances 0.000 description 2
• 238000003149 assay kit Methods 0.000 description 2
• 125000001821 azanediyl group Chemical group [H]N(*)* 0.000 description 2
• 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 2
• 125000002619 bicyclic group Chemical group 0.000 description 2
• 230000004071 biological effect Effects 0.000 description 2
• 239000012455 biphasic mixture Substances 0.000 description 2
• 229910052794 bromium Inorganic materials 0.000 description 2
• 239000000872 buffer Substances 0.000 description 2
• 239000011203 carbon fibre reinforced carbon Substances 0.000 description 2
• 230000004709 cell invasion Effects 0.000 description 2
• 230000001413 cellular effect Effects 0.000 description 2
• 208000019065 cervical carcinoma Diseases 0.000 description 2
• 125000003636 chemical group Chemical group 0.000 description 2
• 239000003638 chemical reducing agent Substances 0.000 description 2
• 125000001309 chloro group Chemical group Cl* 0.000 description 2
• MVPPADPHJFYWMZ-UHFFFAOYSA-N chlorobenzene Chemical compound ClC1=CC=CC=C1 MVPPADPHJFYWMZ-UHFFFAOYSA-N 0.000 description 2
• 238000007796 conventional method Methods 0.000 description 2
• 238000001816 cooling Methods 0.000 description 2
• 229910052593 corundum Inorganic materials 0.000 description 2
• SNRCKKQHDUIRIY-UHFFFAOYSA-L cyclopenta-1,4-dien-1-yl(diphenyl)phosphane;dichloromethane;dichloropalladium;iron(2+) Chemical compound [Fe+2].ClCCl.Cl[Pd]Cl.C1=C[CH-]C(P(C=2C=CC=CC=2)C=2C=CC=CC=2)=C1.C1=C[CH-]C(P(C=2C=CC=CC=2)C=2C=CC=CC=2)=C1 SNRCKKQHDUIRIY-UHFFFAOYSA-L 0.000 description 2
• OPTASPLRGRRNAP-UHFFFAOYSA-N cytosine Chemical compound NC=1C=CNC(=O)N=1 OPTASPLRGRRNAP-UHFFFAOYSA-N 0.000 description 2
• 238000001514 detection method Methods 0.000 description 2
• ALWPRZGDSFAJQS-LXQDYUSJSA-N dideuterio-(2,3-dideuterio-5-fluoro-2,3-dihydro-1-benzofuran-4-yl)methanamine Chemical compound [2H]C(N)(C1=C(C=CC2=C1C(C(O2)[2H])[2H])F)[2H] ALWPRZGDSFAJQS-LXQDYUSJSA-N 0.000 description 2
• ALWPRZGDSFAJQS-BFWBPSQCSA-N dideuterio-(5-fluoro-2,3-dihydro-1-benzofuran-4-yl)methanamine Chemical compound FC=1C=CC2=C(CCO2)C=1C(N)([2H])[2H] ALWPRZGDSFAJQS-BFWBPSQCSA-N 0.000 description 2
• 125000001028 difluoromethyl group Chemical group [H]C(F)(F)* 0.000 description 2
• 238000010828 elution Methods 0.000 description 2
• OIBMEBLCOQCFIT-UHFFFAOYSA-N ethanesulfonyl fluoride Chemical compound CCS(F)(=O)=O OIBMEBLCOQCFIT-UHFFFAOYSA-N 0.000 description 2
• BYPHZHGVWNKAFC-UHFFFAOYSA-N ethenesulfonyl fluoride Chemical compound FS(=O)(=O)C=C BYPHZHGVWNKAFC-UHFFFAOYSA-N 0.000 description 2
• 125000001301 ethoxy group Chemical group [H]C([H])([H])C([H])([H])O* 0.000 description 2
• RVWBLFLLMDHNER-UHFFFAOYSA-N ethyl 3-(2-bromo-6-hydroxyphenyl)propanoate Chemical compound CCOC(=O)CCc1c(O)cccc1Br RVWBLFLLMDHNER-UHFFFAOYSA-N 0.000 description 2
• VICYTAYPKBLQFB-UHFFFAOYSA-N ethyl 3-bromo-2-oxopropanoate Chemical compound CCOC(=O)C(=O)CBr VICYTAYPKBLQFB-UHFFFAOYSA-N 0.000 description 2
• 238000000605 extraction Methods 0.000 description 2
• 239000012091 fetal bovine serum Substances 0.000 description 2
• 125000004216 fluoromethyl group Chemical group [H]C([H])(F)* 0.000 description 2
• 235000019253 formic acid Nutrition 0.000 description 2
• 230000030279 gene silencing Effects 0.000 description 2
• 125000004475 heteroaralkyl group Chemical group 0.000 description 2
• 239000005457 ice water Substances 0.000 description 2
• OUYROQOHZAJXLT-UHFFFAOYSA-N imidazo[1,2-c]pyrimidine-2-carbonitrile Chemical compound N=1C(=CN2C=NC=CC21)C#N OUYROQOHZAJXLT-UHFFFAOYSA-N 0.000 description 2
• 238000000338 in vitro Methods 0.000 description 2
• 238000001727 in vivo Methods 0.000 description 2
• 238000011534 incubation Methods 0.000 description 2
• QWXYZCJEXYQNEI-OSZHWHEXSA-N intermediate I Chemical compound COC(=O)[C@@]1(C=O)[C@H]2CC=[N+](C\C2=C\C)CCc2c1[nH]c1ccccc21 QWXYZCJEXYQNEI-OSZHWHEXSA-N 0.000 description 2
• FMKOJHQHASLBPH-UHFFFAOYSA-N isopropyl iodide Chemical compound CC(C)I FMKOJHQHASLBPH-UHFFFAOYSA-N 0.000 description 2
• 239000007788 liquid Substances 0.000 description 2
• 229910052943 magnesium sulfate Inorganic materials 0.000 description 2
• 235000019341 magnesium sulphate Nutrition 0.000 description 2
• NUJOXMJBOLGQSY-UHFFFAOYSA-N manganese dioxide Chemical compound O=[Mn]=O NUJOXMJBOLGQSY-UHFFFAOYSA-N 0.000 description 2
• 238000004519 manufacturing process Methods 0.000 description 2
• 239000000463 material Substances 0.000 description 2
• 229910052751 metal Inorganic materials 0.000 description 2
• 239000002184 metal Substances 0.000 description 2
• 125000004184 methoxymethyl group Chemical group [H]C([H])([H])OC([H])([H])* 0.000 description 2
• BTCGNEKVCSLSPY-UHFFFAOYSA-N methyl 1-methyl-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyrazole-3-carboxylate Chemical compound CN1N=C(C(=O)OC)C=C1B1OC(C)(C)C(C)(C)O1 BTCGNEKVCSLSPY-UHFFFAOYSA-N 0.000 description 2
• 238000010534 nucleophilic substitution reaction Methods 0.000 description 2
• 125000002524 organometallic group Chemical group 0.000 description 2
• KJIFKLIQANRMOU-UHFFFAOYSA-N oxidanium;4-methylbenzenesulfonate Chemical compound O.CC1=CC=C(S(O)(=O)=O)C=C1 KJIFKLIQANRMOU-UHFFFAOYSA-N 0.000 description 2
• 230000003647 oxidation Effects 0.000 description 2
• 238000007254 oxidation reaction Methods 0.000 description 2
• 125000004430 oxygen atom Chemical group O* 0.000 description 2
• YJVFFLUZDVXJQI-UHFFFAOYSA-L palladium(ii) acetate Chemical compound [Pd+2].CC([O-])=O.CC([O-])=O YJVFFLUZDVXJQI-UHFFFAOYSA-L 0.000 description 2
• MXQOYLRVSVOCQT-UHFFFAOYSA-N palladium;tritert-butylphosphane Chemical compound [Pd].CC(C)(C)P(C(C)(C)C)C(C)(C)C.CC(C)(C)P(C(C)(C)C)C(C)(C)C MXQOYLRVSVOCQT-UHFFFAOYSA-N 0.000 description 2
• 229920002866 paraformaldehyde Polymers 0.000 description 2
• 229940049954 penicillin Drugs 0.000 description 2
• IWELDVXSEVIIGI-UHFFFAOYSA-N piperazin-2-one Chemical compound O=C1CNCCN1 IWELDVXSEVIIGI-UHFFFAOYSA-N 0.000 description 2
• 230000003389 potentiating effect Effects 0.000 description 2
• 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 2
• 125000006239 protecting group Chemical group 0.000 description 2
• 238000000425 proton nuclear magnetic resonance spectrum Methods 0.000 description 2
• 150000003254 radicals Chemical class 0.000 description 2
• NDVLTYZPCACLMA-UHFFFAOYSA-N silver oxide Chemical compound [O-2].[Ag+].[Ag+] NDVLTYZPCACLMA-UHFFFAOYSA-N 0.000 description 2
• 210000003491 skin Anatomy 0.000 description 2
• 239000012312 sodium hydride Substances 0.000 description 2
• LPXPTNMVRIOKMN-UHFFFAOYSA-M sodium nitrite Chemical compound [Na+].[O-]N=O LPXPTNMVRIOKMN-UHFFFAOYSA-M 0.000 description 2
• GEHJYWRUCIMESM-UHFFFAOYSA-L sodium sulfite Chemical compound [Na+].[Na+].[O-]S([O-])=O GEHJYWRUCIMESM-UHFFFAOYSA-L 0.000 description 2
• 230000000392 somatic effect Effects 0.000 description 2
• 229960005322 streptomycin Drugs 0.000 description 2
• 239000000126 substance Substances 0.000 description 2
• 125000004434 sulfur atom Chemical group 0.000 description 2
• VQDKQGKKKXBVMS-UHFFFAOYSA-N tert-butyl 2-(4-bromo-3-methylphenyl)pyrrolidine-1-carboxylate Chemical compound C1=C(Br)C(C)=CC(C2N(CCC2)C(=O)OC(C)(C)C)=C1 VQDKQGKKKXBVMS-UHFFFAOYSA-N 0.000 description 2
• PZDPUQUIZKCNOF-UHFFFAOYSA-N tert-butyl 2-(4-bromophenyl)pyrrolidine-1-carboxylate Chemical compound CC(C)(C)OC(=O)N1CCCC1C1=CC=C(Br)C=C1 PZDPUQUIZKCNOF-UHFFFAOYSA-N 0.000 description 2
• XQQLNXUZFFHOGR-UHFFFAOYSA-N tert-butyl 3-(4-iodophenyl)morpholine-4-carboxylate Chemical compound IC1=CC=C(C=C1)C1N(CCOC1)C(=O)OC(C)(C)C XQQLNXUZFFHOGR-UHFFFAOYSA-N 0.000 description 2
• SZIPGDGOBMFCEH-UHFFFAOYSA-N tert-butyl 6-bromo-3,4-dihydro-1h-isoquinoline-2-carboxylate Chemical compound BrC1=CC=C2CN(C(=O)OC(C)(C)C)CCC2=C1 SZIPGDGOBMFCEH-UHFFFAOYSA-N 0.000 description 2
• TYQGGACMBXIPQA-UHFFFAOYSA-N tert-butyl N-[(5-fluoro-1,3-benzodioxol-4-yl)methyl]carbamate Chemical compound FC1=C(C2=C(OCO2)C=C1)CNC(OC(C)(C)C)=O TYQGGACMBXIPQA-UHFFFAOYSA-N 0.000 description 2
• VPGSXEIYGTTXOE-UHFFFAOYSA-N tert-butyl N-[1-[8-(5-carbamoyl-2-methylpyrazol-3-yl)-5-[(5-fluoro-2,3-dihydro-1-benzofuran-4-yl)methylamino]imidazo[1,2-c]pyrimidin-2-yl]ethyl]carbamate Chemical compound C(N)(=O)C1=NN(C(=C1)C=1C=2N(C(=NC=1)NCC1=C(C=CC3=C1CCO3)F)C=C(N=2)C(C)NC(OC(C)(C)C)=O)C VPGSXEIYGTTXOE-UHFFFAOYSA-N 0.000 description 2
• OJUSVBZNZIBEGN-UHFFFAOYSA-N tert-butyl N-[1-[8-(5-cyano-2-methylpyrazol-3-yl)-5-[(5-fluoro-2,3-dihydro-1-benzofuran-4-yl)methylamino]imidazo[1,2-c]pyrimidin-2-yl]ethyl]carbamate Chemical compound C(#N)C1=NN(C(=C1)C=1C=2N(C(=NC=1)NCC1=C(C=CC3=C1CCO3)F)C=C(N=2)C(C)NC(OC(C)(C)C)=O)C OJUSVBZNZIBEGN-UHFFFAOYSA-N 0.000 description 2
• FPJOPPJXKZEKBE-GUUQVPQOSA-N tert-butyl N-[dideuterio-(2,3-dideuterio-5-fluoro-2,3-dihydro-1-benzofuran-4-yl)methyl]carbamate Chemical compound FC=1C=CC2=C(C(C(O2)[2H])[2H])C=1C([2H])([2H])NC(OC(C)(C)C)=O FPJOPPJXKZEKBE-GUUQVPQOSA-N 0.000 description 2
• FPGGTKZVZWFYPV-UHFFFAOYSA-M tetrabutylammonium fluoride Chemical compound [F-].CCCC[N+](CCCC)(CCCC)CCCC FPGGTKZVZWFYPV-UHFFFAOYSA-M 0.000 description 2
• 230000001225 therapeutic effect Effects 0.000 description 2
• 125000001544 thienyl group Chemical group 0.000 description 2
• FYSNRJHAOHDILO-UHFFFAOYSA-N thionyl chloride Chemical compound ClS(Cl)=O FYSNRJHAOHDILO-UHFFFAOYSA-N 0.000 description 2
• VXUYXOFXAQZZMF-UHFFFAOYSA-N titanium(IV) isopropoxide Chemical compound CC(C)O[Ti](OC(C)C)(OC(C)C)OC(C)C VXUYXOFXAQZZMF-UHFFFAOYSA-N 0.000 description 2
• JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 2
• 230000000699 topical effect Effects 0.000 description 2
• 125000004205 trifluoroethyl group Chemical group [H]C([H])(*)C(F)(F)F 0.000 description 2
• MWKJTNBSKNUMFN-UHFFFAOYSA-N trifluoromethyltrimethylsilane Chemical compound C[Si](C)(C)C(F)(F)F MWKJTNBSKNUMFN-UHFFFAOYSA-N 0.000 description 2
• 210000004881 tumor cell Anatomy 0.000 description 2
• 230000004614 tumor growth Effects 0.000 description 2
• 230000035899 viability Effects 0.000 description 2
• 229910001845 yogo sapphire Inorganic materials 0.000 description 2
• USGAXFCXILPKCB-VIFPVBQESA-N (2S)-1-[3,5-dimethyl-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyrazol-1-yl]propan-2-ol Chemical compound CC1=NN(C(=C1B1OC(C(O1)(C)C)(C)C)C)C[C@H](C)O USGAXFCXILPKCB-VIFPVBQESA-N 0.000 description 1
• MEFKEPWMEQBLKI-QGRBLFOHSA-N (2S)-2-amino-4-[[(2S,3S,4R,5R)-5-(6-aminopurin-9-yl)-3,4-dihydroxyoxolan-2-yl]methyl-(tritritiomethyl)sulfonio]butanoate Chemical compound [3H]C([3H])([3H])[S+](CC[C@H](N)C([O-])=O)C[C@H]1O[C@H]([C@H](O)[C@@H]1O)n1cnc2c(N)ncnc12 MEFKEPWMEQBLKI-QGRBLFOHSA-N 0.000 description 1
• NWZSZGALRFJKBT-KNIFDHDWSA-N (2s)-2,6-diaminohexanoic acid;(2s)-2-hydroxybutanedioic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O.NCCCC[C@H](N)C(O)=O NWZSZGALRFJKBT-KNIFDHDWSA-N 0.000 description 1
• BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 description 1
• 125000004502 1,2,3-oxadiazolyl group Chemical group 0.000 description 1
• 125000004511 1,2,3-thiadiazolyl group Chemical group 0.000 description 1
• 125000001399 1,2,3-triazolyl group Chemical group N1N=NC(=C1)* 0.000 description 1
• 125000004504 1,2,4-oxadiazolyl group Chemical group 0.000 description 1
• 125000004514 1,2,4-thiadiazolyl group Chemical group 0.000 description 1
• 125000001376 1,2,4-triazolyl group Chemical group N1N=C(N=C1)* 0.000 description 1
• 125000004506 1,2,5-oxadiazolyl group Chemical group 0.000 description 1
• 125000004517 1,2,5-thiadiazolyl group Chemical group 0.000 description 1
• 125000001781 1,3,4-oxadiazolyl group Chemical group 0.000 description 1
• 125000004520 1,3,4-thiadiazolyl group Chemical group 0.000 description 1
• WOSCKVGRNOPBKO-UHFFFAOYSA-N 1,3-benzodioxol-4-ylmethanamine Chemical compound NCC1=CC=CC2=C1OCO2 WOSCKVGRNOPBKO-UHFFFAOYSA-N 0.000 description 1
• WJKPUMBLABGUCQ-UHFFFAOYSA-N 1-(4-bromophenyl)-4-chlorobutan-1-one Chemical compound ClCCCC(=O)C1=CC=C(Br)C=C1 WJKPUMBLABGUCQ-UHFFFAOYSA-N 0.000 description 1
• WYECURVXVYPVAT-UHFFFAOYSA-N 1-(4-bromophenyl)ethanone Chemical compound CC(=O)C1=CC=C(Br)C=C1 WYECURVXVYPVAT-UHFFFAOYSA-N 0.000 description 1
• PVOAHINGSUIXLS-UHFFFAOYSA-N 1-Methylpiperazine Chemical compound CN1CCNCC1 PVOAHINGSUIXLS-UHFFFAOYSA-N 0.000 description 1
• TUSDEZXZIZRFGC-UHFFFAOYSA-N 1-O-galloyl-3,6-(R)-HHDP-beta-D-glucose Natural products OC1C(O2)COC(=O)C3=CC(O)=C(O)C(O)=C3C3=C(O)C(O)=C(O)C=C3C(=O)OC1C(O)C2OC(=O)C1=CC(O)=C(O)C(O)=C1 TUSDEZXZIZRFGC-UHFFFAOYSA-N 0.000 description 1
• ZZMDUEFUAMWCKX-UHFFFAOYSA-N 1-[1-[4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl]ethyl]pyrrolidine Chemical compound C=1C=C(B2OC(C)(C)C(C)(C)O2)C=CC=1C(C)N1CCCC1 ZZMDUEFUAMWCKX-UHFFFAOYSA-N 0.000 description 1
• WFAPIZKLEVLUMX-UHFFFAOYSA-N 1-benzofuran-4-carboxylic acid Chemical compound OC(=O)C1=CC=CC2=C1C=CO2 WFAPIZKLEVLUMX-UHFFFAOYSA-N 0.000 description 1
• RJPNVPITBYXBNB-UHFFFAOYSA-N 1-bromo-4-fluoro-2-methylbenzene Chemical compound CC1=CC(F)=CC=C1Br RJPNVPITBYXBNB-UHFFFAOYSA-N 0.000 description 1
• UCCUXODGPMAHRL-UHFFFAOYSA-N 1-bromo-4-iodobenzene Chemical compound BrC1=CC=C(I)C=C1 UCCUXODGPMAHRL-UHFFFAOYSA-N 0.000 description 1
• YWLZMOUAZWHRFP-UHFFFAOYSA-N 1-cyclopropylpyrazole Chemical compound C1CC1N1N=CC=C1 YWLZMOUAZWHRFP-UHFFFAOYSA-N 0.000 description 1
• MRXDFYWQTOWFCK-UHFFFAOYSA-N 1-methyl-2-[4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl]pyrrolidine Chemical compound CN1CCCC1C1=CC=C(C=C1)B1OC(C)(C)C(C)(C)O1 MRXDFYWQTOWFCK-UHFFFAOYSA-N 0.000 description 1
• MVTBZFYDGHFCGH-UHFFFAOYSA-N 1-methyl-4-[6-methyl-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridin-2-yl]piperazine Chemical compound CN1CCN(CC1)C1=NC(C)=C(C=C1)B1OC(C)(C)C(C)(C)O1 MVTBZFYDGHFCGH-UHFFFAOYSA-N 0.000 description 1
• 125000005955 1H-indazolyl group Chemical group 0.000 description 1
• PYHXGXCGESYPCW-UHFFFAOYSA-M 2,2-diphenylacetate Chemical compound C=1C=CC=CC=1C(C(=O)[O-])C1=CC=CC=C1 PYHXGXCGESYPCW-UHFFFAOYSA-M 0.000 description 1
• XVFCNTQRGHDWLM-UHFFFAOYSA-N 2,3-dihydro-1-benzofuran-4-ylmethanamine Chemical compound NCC1=CC=CC2=C1CCO2 XVFCNTQRGHDWLM-UHFFFAOYSA-N 0.000 description 1
• QEENLQKOTDHQEW-UHFFFAOYSA-N 2,5-dibromo-3-fluoropyridine Chemical compound FC1=CC(Br)=CN=C1Br QEENLQKOTDHQEW-UHFFFAOYSA-N 0.000 description 1
• IOMSEKKIFCQYHF-UHFFFAOYSA-N 2-(1,3-dioxolan-2-yl)-4-methyl-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridine Chemical compound CC1=CC(=NC=C1B1OC(C)(C)C(C)(C)O1)C1OCCO1 IOMSEKKIFCQYHF-UHFFFAOYSA-N 0.000 description 1
• BPSZKOJWQQLLEI-UHFFFAOYSA-N 2-(2-methoxyethoxy)-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyrimidine Chemical compound COCCOc1ncc(cn1)B1OC(C)(C)C(C)(C)O1 BPSZKOJWQQLLEI-UHFFFAOYSA-N 0.000 description 1
• JFLBFTBAXZNXHS-UHFFFAOYSA-N 2-(4-bromo-3-methylphenyl)pyrrolidine Chemical compound C1=C(Br)C(C)=CC(C2NCCC2)=C1 JFLBFTBAXZNXHS-UHFFFAOYSA-N 0.000 description 1
• ZSZCXAOQVBEPME-UHFFFAOYSA-N 2-(4-bromophenyl)ethanamine Chemical compound NCCC1=CC=C(Br)C=C1 ZSZCXAOQVBEPME-UHFFFAOYSA-N 0.000 description 1
• MWPSTGBQHPBARW-UHFFFAOYSA-N 2-(4-diethoxyphosphorylphenyl)-4,4,5,5-tetramethyl-1,3,2-dioxaborolane Chemical compound C1=CC(P(=O)(OCC)OCC)=CC=C1B1OC(C)(C)C(C)(C)O1 MWPSTGBQHPBARW-UHFFFAOYSA-N 0.000 description 1
• XNWFRZJHXBZDAG-UHFFFAOYSA-N 2-METHOXYETHANOL Chemical compound COCCO XNWFRZJHXBZDAG-UHFFFAOYSA-N 0.000 description 1
• RBTQVTBGPZKNCK-UHFFFAOYSA-N 2-[(dimethylamino)methyl]-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzonitrile Chemical compound CN(C)CC1=C(C=C(C=C1)B1OC(C)(C)C(C)(C)O1)C#N RBTQVTBGPZKNCK-UHFFFAOYSA-N 0.000 description 1
• NWMHVSWWXKSMPG-UHFFFAOYSA-N 2-[4-(1,3-dioxolan-2-yl)-2-methylphenyl]-4,4,5,5-tetramethyl-1,3,2-dioxaborolane Chemical compound CC1=C(C=CC(=C1)C1OCCO1)B1OC(C)(C)C(C)(C)O1 NWMHVSWWXKSMPG-UHFFFAOYSA-N 0.000 description 1
• QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 1
• ASSKVPFEZFQQNQ-UHFFFAOYSA-N 2-benzoxazolinone Chemical group C1=CC=C2OC(O)=NC2=C1 ASSKVPFEZFQQNQ-UHFFFAOYSA-N 0.000 description 1
• LQTXMBDCLHZDAM-UHFFFAOYSA-N 2-bromo-6-hydroxybenzaldehyde Chemical compound OC1=CC=CC(Br)=C1C=O LQTXMBDCLHZDAM-UHFFFAOYSA-N 0.000 description 1
• XHTCFGOMUQRUTK-UHFFFAOYSA-N 2-cyclopropyl-4-methyl-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyrimidine Chemical compound C1(CC1)C1=NC=C(C(=N1)C)B1OC(C(O1)(C)C)(C)C XHTCFGOMUQRUTK-UHFFFAOYSA-N 0.000 description 1
• LOSVCXVTPBAUOU-UHFFFAOYSA-N 2-methoxy-4-methyl-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridine Chemical compound C1=NC(OC)=CC(C)=C1B1OC(C)(C)C(C)(C)O1 LOSVCXVTPBAUOU-UHFFFAOYSA-N 0.000 description 1
• YPUNMFKZCYFCTA-UHFFFAOYSA-N 2-methoxy-4-methyl-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyrimidine Chemical compound COc1ncc(B2OC(C)(C)C(C)(C)O2)c(C)n1 YPUNMFKZCYFCTA-UHFFFAOYSA-N 0.000 description 1
• FETGYHZBHOFHJX-UHFFFAOYSA-N 2-methyl-4-trimethylstannylpyridazin-3-one Chemical compound CN1N=CC=C(C1=O)[Sn](C)(C)C FETGYHZBHOFHJX-UHFFFAOYSA-N 0.000 description 1
• QRMAQYCEYDOEGC-UHFFFAOYSA-N 2-methyl-6-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-3,4-dihydro-1h-isoquinoline Chemical compound C=1C=C2CN(C)CCC2=CC=1B1OC(C)(C)C(C)(C)O1 QRMAQYCEYDOEGC-UHFFFAOYSA-N 0.000 description 1
• BUOUXUXFUAMANS-UHFFFAOYSA-N 2-methyl-6-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-3,4-dihydroisoquinolin-1-one Chemical compound C=1C=C2C(=O)N(C)CCC2=CC=1B1OC(C)(C)C(C)(C)O1 BUOUXUXFUAMANS-UHFFFAOYSA-N 0.000 description 1
• LBLYYCQCTBFVLH-UHFFFAOYSA-M 2-methylbenzenesulfonate Chemical compound CC1=CC=CC=C1S([O-])(=O)=O LBLYYCQCTBFVLH-UHFFFAOYSA-M 0.000 description 1
• 125000000094 2-phenylethyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])([H])* 0.000 description 1
• UAIUNKRWKOVEES-UHFFFAOYSA-N 3,3',5,5'-tetramethylbenzidine Chemical compound CC1=C(N)C(C)=CC(C=2C=C(C)C(N)=C(C)C=2)=C1 UAIUNKRWKOVEES-UHFFFAOYSA-N 0.000 description 1
• DJZUBJSMAJTEDF-UHFFFAOYSA-N 3,5-dimethyl-1-propan-2-yl-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyrazole Chemical compound CC(C)N1N=C(C)C(B2OC(C)(C)C(C)(C)O2)=C1C DJZUBJSMAJTEDF-UHFFFAOYSA-N 0.000 description 1
• BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 description 1
• JGGHLJKQQVOMMG-UHFFFAOYSA-N 3-bromo-2-(bromomethyl)benzonitrile Chemical compound BrCC1=C(Br)C=CC=C1C#N JGGHLJKQQVOMMG-UHFFFAOYSA-N 0.000 description 1
• HXQRAQKAGXRFEM-UHFFFAOYSA-N 3-bromo-4-fluorobenzenethiol Chemical compound FC1=CC=C(S)C=C1Br HXQRAQKAGXRFEM-UHFFFAOYSA-N 0.000 description 1
• GUYGQQWIKZLHTP-UHFFFAOYSA-N 3-bromo-6-fluoro-2-methylpyridine Chemical compound CC1=NC(F)=CC=C1Br GUYGQQWIKZLHTP-UHFFFAOYSA-N 0.000 description 1
• MNOJRWOWILAHAV-UHFFFAOYSA-N 3-bromophenol Chemical compound OC1=CC=CC(Br)=C1 MNOJRWOWILAHAV-UHFFFAOYSA-N 0.000 description 1
• NALQATLYFUYUND-UHFFFAOYSA-N 3-methyl-1-propan-2-yl-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyrazole Chemical compound CC1=NN(C(C)C)C=C1B1OC(C)(C)C(C)(C)O1 NALQATLYFUYUND-UHFFFAOYSA-N 0.000 description 1
• MHZXKVPCJBPNKI-UHFFFAOYSA-N 3-phenylmorpholine Chemical compound N1CCOCC1C1=CC=CC=C1 MHZXKVPCJBPNKI-UHFFFAOYSA-N 0.000 description 1
• UCFSYHMCKWNKAH-UHFFFAOYSA-N 4,4,5,5-tetramethyl-1,3,2-dioxaborolane Chemical compound CC1(C)OBOC1(C)C UCFSYHMCKWNKAH-UHFFFAOYSA-N 0.000 description 1
• QHDJBVYKNWMESU-UHFFFAOYSA-N 4,4,5,5-tetramethyl-2-[2-methyl-4-(trifluoromethylsulfonyl)phenyl]-1,3,2-dioxaborolane Chemical compound CC1=CC(S(=O)(=O)C(F)(F)F)=CC=C1B1OC(C)(C)C(C)(C)O1 QHDJBVYKNWMESU-UHFFFAOYSA-N 0.000 description 1
• GYYRSVYQIKGKNM-UHFFFAOYSA-N 4,4,5,5-tetramethyl-2-[4-(oxolan-2-yl)phenyl]-1,3,2-dioxaborolane Chemical compound CC1(C)OB(OC1(C)C)c1ccc(cc1)C1CCCO1 GYYRSVYQIKGKNM-UHFFFAOYSA-N 0.000 description 1
• OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 1
• XDDLLUBKOZYOMY-UHFFFAOYSA-N 4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzenesulfonamide Chemical compound O1C(C)(C)C(C)(C)OB1C1=CC=C(S(N)(=O)=O)C=C1 XDDLLUBKOZYOMY-UHFFFAOYSA-N 0.000 description 1
• GAMYYCRTACQSBR-UHFFFAOYSA-N 4-azabenzimidazole Chemical compound C1=CC=C2NC=NC2=N1 GAMYYCRTACQSBR-UHFFFAOYSA-N 0.000 description 1
• PSKJIHDVFDVNBU-UHFFFAOYSA-N 4-bromo-3-chlorobenzoic acid Chemical compound OC(=O)C1=CC=C(Br)C(Cl)=C1 PSKJIHDVFDVNBU-UHFFFAOYSA-N 0.000 description 1
• MMEGELSFOYDPQW-UHFFFAOYSA-N 4-bromo-3-methylaniline Chemical compound CC1=CC(N)=CC=C1Br MMEGELSFOYDPQW-UHFFFAOYSA-N 0.000 description 1
• WFCWVKYWFMORLD-UHFFFAOYSA-N 4-bromo-n,n,3-trimethylbenzamide Chemical compound CN(C)C(=O)C1=CC=C(Br)C(C)=C1 WFCWVKYWFMORLD-UHFFFAOYSA-N 0.000 description 1
• KMMHZIBWCXYAAH-UHFFFAOYSA-N 4-bromobenzenesulfonyl chloride Chemical compound ClS(=O)(=O)C1=CC=C(Br)C=C1 KMMHZIBWCXYAAH-UHFFFAOYSA-N 0.000 description 1
• KLYYNZMCPPVPIA-UHFFFAOYSA-N 4-chloro-2-methoxy-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyridine Chemical compound COC1=NC=C(B2OC(C)(C)C(C)(C)O2)C(Cl)=C1 KLYYNZMCPPVPIA-UHFFFAOYSA-N 0.000 description 1
• LQRYNSXUJNYQBP-UHFFFAOYSA-N 4-methyl-2-propan-2-yloxy-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyrimidine Chemical compound C(C)(C)OC1=NC=C(C(=N1)C)B1OC(C(O1)(C)C)(C)C LQRYNSXUJNYQBP-UHFFFAOYSA-N 0.000 description 1
• 125000005986 4-piperidonyl group Chemical group 0.000 description 1
• TXNLQUKVUJITMX-UHFFFAOYSA-N 4-tert-butyl-2-(4-tert-butylpyridin-2-yl)pyridine Chemical compound CC(C)(C)C1=CC=NC(C=2N=CC=C(C=2)C(C)(C)C)=C1 TXNLQUKVUJITMX-UHFFFAOYSA-N 0.000 description 1
• 125000002471 4H-quinolizinyl group Chemical group C=1(C=CCN2C=CC=CC12)* 0.000 description 1
• QRCGFTXRXYMJOS-UHFFFAOYSA-N 4h-1,4-benzoxazin-3-one Chemical group C1=CC=C2NC(=O)COC2=C1 QRCGFTXRXYMJOS-UHFFFAOYSA-N 0.000 description 1
• XPGIBDJXEVAVTO-UHFFFAOYSA-N 5-bromo-2-chloropyrimidine Chemical compound ClC1=NC=C(Br)C=N1 XPGIBDJXEVAVTO-UHFFFAOYSA-N 0.000 description 1
• HTBPXLJKMNBQMS-UHFFFAOYSA-N 5-bromo-2-methoxy-4-methylpyridine Chemical compound COC1=CC(C)=C(Br)C=N1 HTBPXLJKMNBQMS-UHFFFAOYSA-N 0.000 description 1
• KTPLBYFKHPABLJ-UHFFFAOYSA-N 5-bromo-4-chloro-2-methoxypyridine Chemical compound COC1=CC(Cl)=C(Br)C=N1 KTPLBYFKHPABLJ-UHFFFAOYSA-N 0.000 description 1
• PKKXSXWOKVKYOW-UHFFFAOYSA-N 5-bromo-4-methylpyridine-2-carbaldehyde Chemical compound CC1=CC(C=O)=NC=C1Br PKKXSXWOKVKYOW-UHFFFAOYSA-N 0.000 description 1
• UYWAYTBDMJFIQT-UHFFFAOYSA-N 5-chloro-1h-pyridazin-6-one Chemical compound ClC1=CC=NNC1=O UYWAYTBDMJFIQT-UHFFFAOYSA-N 0.000 description 1
• GCPUMFAGCOLKAK-UHFFFAOYSA-N 5-fluoro-1,3-benzodioxole Chemical compound FC1=CC=C2OCOC2=C1 GCPUMFAGCOLKAK-UHFFFAOYSA-N 0.000 description 1
• FTVHMXRCGNWCOL-UHFFFAOYSA-N 5-fluoro-1-benzofuran Chemical compound FC1=CC=C2OC=CC2=C1 FTVHMXRCGNWCOL-UHFFFAOYSA-N 0.000 description 1
• DZGWFLTYHFQNTP-UHFFFAOYSA-N 5-methyl-1-propan-2-yl-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyrazole Chemical compound CC(C)N1N=CC(B2OC(C)(C)C(C)(C)O2)=C1C DZGWFLTYHFQNTP-UHFFFAOYSA-N 0.000 description 1
• MSJAEFFWTBMIKT-UHFFFAOYSA-N 5-methyl-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1h-pyrazole Chemical compound CC1=NNC=C1B1OC(C)(C)C(C)(C)O1 MSJAEFFWTBMIKT-UHFFFAOYSA-N 0.000 description 1
• FQPKKECSRKYXIZ-UHFFFAOYSA-N 6-bromo-3,4-dihydro-2h-isoquinolin-1-one Chemical compound O=C1NCCC2=CC(Br)=CC=C21 FQPKKECSRKYXIZ-UHFFFAOYSA-N 0.000 description 1
• 206010069754 Acquired gene mutation Diseases 0.000 description 1
• 208000028564 B-cell non-Hodgkin lymphoma Diseases 0.000 description 1
• 239000005711 Benzoic acid Substances 0.000 description 1
• VJONJTQNAWDLNJ-RJSZUWSASA-N BrC1=C(C=C(C=C1)C(N(C)C)([2H])[2H])C Chemical compound BrC1=C(C=C(C=C1)C(N(C)C)([2H])[2H])C VJONJTQNAWDLNJ-RJSZUWSASA-N 0.000 description 1
• WEROVYOUOIXAEC-QWYIBYNOSA-N BrC=1C=2N(C(=NC=1)NC([2H])([2H])C1=C(C=CC3=C1C(C(O3)[2H])[2H])F)C=C(N=2)C#N Chemical compound BrC=1C=2N(C(=NC=1)NC([2H])([2H])C1=C(C=CC3=C1C(C(O3)[2H])[2H])F)C=C(N=2)C#N WEROVYOUOIXAEC-QWYIBYNOSA-N 0.000 description 1
• WEROVYOUOIXAEC-NCYHJHSESA-N BrC=1C=2N(C(=NC=1)NC([2H])([2H])C1=C(C=CC3=C1CCO3)F)C=C(N=2)C#N Chemical compound BrC=1C=2N(C(=NC=1)NC([2H])([2H])C1=C(C=CC3=C1CCO3)F)C=C(N=2)C#N WEROVYOUOIXAEC-NCYHJHSESA-N 0.000 description 1
• KUYNWYKUYASDQY-UHFFFAOYSA-N BrC=1C=2N(C(=NC=1)NCC1=C(C=CC3=C1CCO3)F)C=C(N=2)C(=O)C1=CC=CC=C1 Chemical compound BrC=1C=2N(C(=NC=1)NCC1=C(C=CC3=C1CCO3)F)C=C(N=2)C(=O)C1=CC=CC=C1 KUYNWYKUYASDQY-UHFFFAOYSA-N 0.000 description 1
• CPELXLSAUQHCOX-UHFFFAOYSA-M Bromide Chemical compound [Br-] CPELXLSAUQHCOX-UHFFFAOYSA-M 0.000 description 1
• UQIIDQMFDGEUGU-UHFFFAOYSA-N C(C)(C)(C)OC(=O)NC(C)C=1N=C2N(C(=NC=C2C2=CC(=NN2C)C(=O)OC)NCC2=C(C=CC3=C2CCO3)F)C=1 Chemical compound C(C)(C)(C)OC(=O)NC(C)C=1N=C2N(C(=NC=C2C2=CC(=NN2C)C(=O)OC)NCC2=C(C=CC3=C2CCO3)F)C=1 UQIIDQMFDGEUGU-UHFFFAOYSA-N 0.000 description 1
• MIMLDSJNCBWTCY-UHFFFAOYSA-N C(C)(C)(C)OC(=O)OCC=1N=C2N(C(=NC=C2C2=CC(=NN2C)C)OC(NCC2=C(C=CC3=C2CCO3)F)=O)C=1 Chemical compound C(C)(C)(C)OC(=O)OCC=1N=C2N(C(=NC=C2C2=CC(=NN2C)C)OC(NCC2=C(C=CC3=C2CCO3)F)=O)C=1 MIMLDSJNCBWTCY-UHFFFAOYSA-N 0.000 description 1
• NTKLURKMZLCMOD-UHFFFAOYSA-N C1=C(C2=NC(=CN2C(=N1)Cl)C(=O)O)Br Chemical compound C1=C(C2=NC(=CN2C(=N1)Cl)C(=O)O)Br NTKLURKMZLCMOD-UHFFFAOYSA-N 0.000 description 1
• 125000000041 C6-C10 aryl group Chemical group 0.000 description 1
• GURRSFJVHFYQRX-UHFFFAOYSA-N CCOC(=O)C1=CN2C(=N1)C(Br)=CN=C2NCC1=C(Cl)C=CC2=C1CCO2 Chemical compound CCOC(=O)C1=CN2C(=N1)C(Br)=CN=C2NCC1=C(Cl)C=CC2=C1CCO2 GURRSFJVHFYQRX-UHFFFAOYSA-N 0.000 description 1
• YIFYTUUXQXINSX-UHFFFAOYSA-N CCOC(=O)C1=CN2C(=N1)C(Br)=CN=C2NCC1=C2CCCOC2=CC=C1 Chemical compound CCOC(=O)C1=CN2C(=N1)C(Br)=CN=C2NCC1=C2CCCOC2=CC=C1 YIFYTUUXQXINSX-UHFFFAOYSA-N 0.000 description 1
• IRDZOTMVTNYKGY-UHFFFAOYSA-N CCOC(=O)C1=CN2C(=N1)C(Br)=CN=C2NCC1=CC=CC2=C1OCO2 Chemical compound CCOC(=O)C1=CN2C(=N1)C(Br)=CN=C2NCC1=CC=CC2=C1OCO2 IRDZOTMVTNYKGY-UHFFFAOYSA-N 0.000 description 1
• VAKHTUXHBLARLM-UHFFFAOYSA-N CN1N=C(C=C1C=1C=2N(C(=NC=1)N(C(OC(C)(C)C)=O)CC1=C(C=CC3=C1CCO3)F)C=C(N=2)C(C(F)(F)F)=O)C Chemical compound CN1N=C(C=C1C=1C=2N(C(=NC=1)N(C(OC(C)(C)C)=O)CC1=C(C=CC3=C1CCO3)F)C=C(N=2)C(C(F)(F)F)=O)C VAKHTUXHBLARLM-UHFFFAOYSA-N 0.000 description 1
• PDIOGMZANVLCAM-UHFFFAOYSA-N CN1N=C(C=C1C=1C=2N(C(=NC=1)NCC1=C(C=CC3=C1CCO3)F)C=C(N=2)CNCCS(=O)(=O)F)C Chemical compound CN1N=C(C=C1C=1C=2N(C(=NC=1)NCC1=C(C=CC3=C1CCO3)F)C=C(N=2)CNCCS(=O)(=O)F)C PDIOGMZANVLCAM-UHFFFAOYSA-N 0.000 description 1
• GAWIXWVDTYZWAW-UHFFFAOYSA-N C[CH]O Chemical group C[CH]O GAWIXWVDTYZWAW-UHFFFAOYSA-N 0.000 description 1
• 101710167800 Capsid assembly scaffolding protein Proteins 0.000 description 1
• 206010008263 Cervical dysplasia Diseases 0.000 description 1
• VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
• KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
• KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
• 206010014733 Endometrial cancer Diseases 0.000 description 1
• 206010014759 Endometrial neoplasm Diseases 0.000 description 1
• 239000004593 Epoxy Substances 0.000 description 1
• HJKJJEQPDICQDQ-UHFFFAOYSA-N FC(C(=O)O[IH]OC(C(F)(F)F)=O)(F)F Chemical compound FC(C(=O)O[IH]OC(C(F)(F)F)=O)(F)F HJKJJEQPDICQDQ-UHFFFAOYSA-N 0.000 description 1
• CCLRDVAVQVVNKH-UHFFFAOYSA-N FC1=C(CNC2=NC=C(Br)C3=NC(=CN23)C#N)C2=C(OCO2)C=C1 Chemical compound FC1=C(CNC2=NC=C(Br)C3=NC(=CN23)C#N)C2=C(OCO2)C=C1 CCLRDVAVQVVNKH-UHFFFAOYSA-N 0.000 description 1
• PURVDSHFGRMOAY-UHFFFAOYSA-N FC1=CC=C2SC=CC2=C1NC1=NC=C(Br)C2=NC(=CN12)C#N Chemical compound FC1=CC=C2SC=CC2=C1NC1=NC=C(Br)C2=NC(=CN12)C#N PURVDSHFGRMOAY-UHFFFAOYSA-N 0.000 description 1
• 239000001263 FEMA 3042 Substances 0.000 description 1
• AEMRFAOFKBGASW-UHFFFAOYSA-M Glycolate Chemical compound OCC([O-])=O AEMRFAOFKBGASW-UHFFFAOYSA-M 0.000 description 1
• 239000007818 Grignard reagent Substances 0.000 description 1
• 102100039869 Histone H2B type F-S Human genes 0.000 description 1
• 102000003964 Histone deacetylase Human genes 0.000 description 1
• 108090000353 Histone deacetylase Proteins 0.000 description 1
• 101001035372 Homo sapiens Histone H2B type F-S Proteins 0.000 description 1
• DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
• 206010061523 Lip and/or oral cavity cancer Diseases 0.000 description 1
• 206010058467 Lung neoplasm malignant Diseases 0.000 description 1
• AFVFQIVMOAPDHO-UHFFFAOYSA-M Methanesulfonate Chemical compound CS([O-])(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-M 0.000 description 1
• JPMVFMHDHRMGHD-UHFFFAOYSA-N N,N-dimethyl-1-[3-methyl-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl]methanamine Chemical compound CN(C)Cc1ccc(B2OC(C)(C)C(C)(C)O2)c(C)c1 JPMVFMHDHRMGHD-UHFFFAOYSA-N 0.000 description 1
• UWEUYVUVIHWCSI-UHFFFAOYSA-N NCC=1N=C2N(C(=NC=C2C2=C(C=C(C=C2)S(=O)(=O)C)C)NCC2=C(C=CC3=C2CCO3)F)C=1 Chemical compound NCC=1N=C2N(C(=NC=C2C2=C(C=C(C=C2)S(=O)(=O)C)C)NCC2=C(C=CC3=C2CCO3)F)C=1 UWEUYVUVIHWCSI-UHFFFAOYSA-N 0.000 description 1
• 101100030361 Neurospora crassa (strain ATCC 24698 / 74-OR23-1A / CBS 708.71 / DSM 1257 / FGSC 987) pph-3 gene Proteins 0.000 description 1
• GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 1
• 229910019142 PO4 Inorganic materials 0.000 description 1
• 229920002230 Pectic acid Polymers 0.000 description 1
• LRBQNJMCXXYXIU-PPKXGCFTSA-N Penta-digallate-beta-D-glucose Natural products OC1=C(O)C(O)=CC(C(=O)OC=2C(=C(O)C=C(C=2)C(=O)OC[C@@H]2[C@H]([C@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)[C@@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)[C@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)O2)OC(=O)C=2C=C(OC(=O)C=3C=C(O)C(O)=C(O)C=3)C(O)=C(O)C=2)O)=C1 LRBQNJMCXXYXIU-PPKXGCFTSA-N 0.000 description 1
• 108010020346 Polyglutamic Acid Proteins 0.000 description 1
• 101710130420 Probable capsid assembly scaffolding protein Proteins 0.000 description 1
• GOOHAUXETOMSMM-VKHMYHEASA-N S-propylene oxide Chemical compound C[C@H]1CO1 GOOHAUXETOMSMM-VKHMYHEASA-N 0.000 description 1
• 229910006124 SOCl2 Inorganic materials 0.000 description 1
• 101710204410 Scaffold protein Proteins 0.000 description 1
• VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 1
• HEMHJVSKTPXQMS-DYCDLGHISA-M Sodium hydroxide-d Chemical compound [Na+].[2H][O-] HEMHJVSKTPXQMS-DYCDLGHISA-M 0.000 description 1
• KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 1
• FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
• 208000024770 Thyroid neoplasm Diseases 0.000 description 1
• GCTFWCDSFPMHHS-UHFFFAOYSA-M Tributyltin chloride Chemical compound CCCC[Sn](Cl)(CCCC)CCCC GCTFWCDSFPMHHS-UHFFFAOYSA-M 0.000 description 1
• BBAWTPDTGRXPDG-UHFFFAOYSA-N [1,3]thiazolo[4,5-b]pyridine Chemical compound C1=CC=C2SC=NC2=N1 BBAWTPDTGRXPDG-UHFFFAOYSA-N 0.000 description 1
• SJHGLGQNOXMVMK-UHFFFAOYSA-N [2-[[(2-methylpropan-2-yl)oxycarbonylamino]methyl]pyrimidin-5-yl]boronic acid Chemical compound CC(C)(C)OC(=O)NCC1=NC=C(B(O)O)C=N1 SJHGLGQNOXMVMK-UHFFFAOYSA-N 0.000 description 1
• XDXLWGSWGUHJAJ-UHFFFAOYSA-N [2-chloro-4-(dimethylcarbamoyl)phenyl]boronic acid Chemical compound CN(C)C(=O)C1=CC=C(B(O)O)C(Cl)=C1 XDXLWGSWGUHJAJ-UHFFFAOYSA-N 0.000 description 1
• DZAGVBCFKDESAK-UHFFFAOYSA-N [6-(1,3-dioxolan-2-yl)-5-fluoro-4-methylpyridin-3-yl]boronic acid Chemical compound O1C(OCC1)C1=C(C(=C(C=N1)B(O)O)C)F DZAGVBCFKDESAK-UHFFFAOYSA-N 0.000 description 1
• 238000002835 absorbance Methods 0.000 description 1
• 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 description 1
• 230000002378 acidificating effect Effects 0.000 description 1
• 125000000641 acridinyl group Chemical group C1(=CC=CC2=NC3=CC=CC=C3C=C12)* 0.000 description 1
• 239000004480 active ingredient Substances 0.000 description 1
• 125000002252 acyl group Chemical group 0.000 description 1
• 230000006978 adaptation Effects 0.000 description 1
• 239000002671 adjuvant Substances 0.000 description 1
• 150000001299 aldehydes Chemical class 0.000 description 1
• 239000000783 alginic acid Substances 0.000 description 1
• 229960001126 alginic acid Drugs 0.000 description 1
• 235000010443 alginic acid Nutrition 0.000 description 1
• 229920000615 alginic acid Polymers 0.000 description 1
• 150000004781 alginic acids Chemical class 0.000 description 1
• 125000004448 alkyl carbonyl group Chemical group 0.000 description 1
• 150000004791 alkyl magnesium halides Chemical class 0.000 description 1
• IYABWNGZIDDRAK-UHFFFAOYSA-N allene Chemical group C=C=C IYABWNGZIDDRAK-UHFFFAOYSA-N 0.000 description 1
• HSFWRNGVRCDJHI-UHFFFAOYSA-N alpha-acetylene Natural products C#C HSFWRNGVRCDJHI-UHFFFAOYSA-N 0.000 description 1
• 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
• 230000001668 ameliorated effect Effects 0.000 description 1
• 125000002178 anthracenyl group Chemical group C1(=CC=CC2=CC3=CC=CC=C3C=C12)* 0.000 description 1
• 230000000118 anti-neoplastic effect Effects 0.000 description 1
• 229940034982 antineoplastic agent Drugs 0.000 description 1
• 229940072107 ascorbate Drugs 0.000 description 1
• 229960005070 ascorbic acid Drugs 0.000 description 1
• 230000003140 astrocytic effect Effects 0.000 description 1
• HGQULGDOROIPJN-UHFFFAOYSA-N azetidin-1-ium;chloride Chemical compound Cl.C1CNC1 HGQULGDOROIPJN-UHFFFAOYSA-N 0.000 description 1
• 125000004069 aziridinyl group Chemical group 0.000 description 1
• 125000004931 azocinyl group Chemical group N1=C(C=CC=CC=C1)* 0.000 description 1
• HUMNYLRZRPPJDN-UHFFFAOYSA-N benzaldehyde Chemical compound O=CC1=CC=CC=C1 HUMNYLRZRPPJDN-UHFFFAOYSA-N 0.000 description 1
• 125000003785 benzimidazolyl group Chemical group N1=C(NC2=C1C=CC=C2)* 0.000 description 1
• 125000004604 benzisothiazolyl group Chemical group S1N=C(C2=C1C=CC=C2)* 0.000 description 1
• 125000004603 benzisoxazolyl group Chemical group O1N=C(C2=C1C=CC=C2)* 0.000 description 1
• 229940050390 benzoate Drugs 0.000 description 1
• 125000000499 benzofuranyl group Chemical group O1C(=CC2=C1C=CC=C2)* 0.000 description 1
• 235000010233 benzoic acid Nutrition 0.000 description 1
• 125000001164 benzothiazolyl group Chemical group S1C(=NC2=C1C=CC=C2)* 0.000 description 1
• 125000004196 benzothienyl group Chemical group S1C(=CC2=C1C=CC=C2)* 0.000 description 1
• 125000004541 benzoxazolyl group Chemical group O1C(=NC2=C1C=CC=C2)* 0.000 description 1
• 125000005512 benztetrazolyl group Chemical group 0.000 description 1
• 239000003181 biological factor Substances 0.000 description 1
• 201000011263 bladder neck cancer Diseases 0.000 description 1
• 230000037396 body weight Effects 0.000 description 1
• 238000006664 bond formation reaction Methods 0.000 description 1
• MKJQIOMCOYQKNP-UHFFFAOYSA-N bromomethane;magnesium Chemical compound [Mg].BrC MKJQIOMCOYQKNP-UHFFFAOYSA-N 0.000 description 1
• KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 description 1
• 125000004369 butenyl group Chemical group C(=CCC)* 0.000 description 1
• 125000005569 butenylene group Chemical group 0.000 description 1
• 125000000480 butynyl group Chemical group [*]C#CC([H])([H])C([H])([H])[H] 0.000 description 1
• 125000005622 butynylene group Chemical group 0.000 description 1
• 239000004202 carbamide Substances 0.000 description 1
• 125000000609 carbazolyl group Chemical group C1(=CC=CC=2C3=CC=CC=C3NC12)* 0.000 description 1
• 125000004623 carbolinyl group Chemical group 0.000 description 1
• 229910052799 carbon Inorganic materials 0.000 description 1
• 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 1
• 150000007942 carboxylates Chemical class 0.000 description 1
• 238000004113 cell culture Methods 0.000 description 1
• 239000013592 cell lysate Substances 0.000 description 1
• 230000005754 cellular signaling Effects 0.000 description 1
• 210000003679 cervix uteri Anatomy 0.000 description 1
• 239000007795 chemical reaction product Substances 0.000 description 1
• 238000002512 chemotherapy Methods 0.000 description 1
• 239000012069 chiral reagent Substances 0.000 description 1
• 125000004218 chloromethyl group Chemical group [H]C([H])(Cl)* 0.000 description 1
• 125000003016 chromanyl group Chemical group O1C(CCC2=CC=CC=C12)* 0.000 description 1
• 125000004230 chromenyl group Chemical group O1C(C=CC2=CC=CC=C12)* 0.000 description 1
• WBYWAXJHAXSJNI-UHFFFAOYSA-N cinnamic acid Chemical compound OC(=O)C=CC1=CC=CC=C1 WBYWAXJHAXSJNI-UHFFFAOYSA-N 0.000 description 1
• 125000000259 cinnolinyl group Chemical group N1=NC(=CC2=CC=CC=C12)* 0.000 description 1
• 229940001468 citrate Drugs 0.000 description 1
• PDZKZMQQDCHTNF-UHFFFAOYSA-M copper(1+);thiocyanate Chemical compound [Cu+].[S-]C#N PDZKZMQQDCHTNF-UHFFFAOYSA-M 0.000 description 1
• KZZKOVLJUKWSKX-UHFFFAOYSA-N cyclobutanamine Chemical compound NC1CCC1 KZZKOVLJUKWSKX-UHFFFAOYSA-N 0.000 description 1
• 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
• 125000000582 cycloheptyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
• 125000000596 cyclohexenyl group Chemical group C1(=CCCCC1)* 0.000 description 1
• 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
• 125000000640 cyclooctyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C([H])([H])C1([H])[H] 0.000 description 1
• 125000002433 cyclopentenyl group Chemical group C1(=CCCC1)* 0.000 description 1
• 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
• JRYOZJIRAVZGMV-UHFFFAOYSA-N cyclopropanecarboximidamide;hydron;chloride Chemical compound Cl.NC(=N)C1CC1 JRYOZJIRAVZGMV-UHFFFAOYSA-N 0.000 description 1
• 208000002445 cystadenocarcinoma Diseases 0.000 description 1
• 229940104302 cytosine Drugs 0.000 description 1
• 125000004856 decahydroquinolinyl group Chemical group N1(CCCC2CCCCC12)* 0.000 description 1
• 238000011161 development Methods 0.000 description 1
• 230000018109 developmental process Effects 0.000 description 1
• 229940061607 dibasic sodium phosphate Drugs 0.000 description 1
• LXCYSACZTOKNNS-UHFFFAOYSA-N diethoxy(oxo)phosphanium Chemical compound CCO[P+](=O)OCC LXCYSACZTOKNNS-UHFFFAOYSA-N 0.000 description 1
• 125000006001 difluoroethyl group Chemical group 0.000 description 1
• 229940043279 diisopropylamine Drugs 0.000 description 1
• 238000010790 dilution Methods 0.000 description 1
• 239000012895 dilution Substances 0.000 description 1
• 125000005879 dioxolanyl group Chemical group 0.000 description 1
• BNIILDVGGAEEIG-UHFFFAOYSA-L disodium hydrogen phosphate Chemical compound [Na+].[Na+].OP([O-])([O-])=O BNIILDVGGAEEIG-UHFFFAOYSA-L 0.000 description 1
• 125000005883 dithianyl group Chemical group 0.000 description 1
• 229940079593 drug Drugs 0.000 description 1
• 201000003914 endometrial carcinoma Diseases 0.000 description 1
• 238000006911 enzymatic reaction Methods 0.000 description 1
• 230000001973 epigenetic effect Effects 0.000 description 1
• 210000002919 epithelial cell Anatomy 0.000 description 1
• 150000002148 esters Chemical class 0.000 description 1
• 125000005678 ethenylene group Chemical group [H]C([*:1])=C([H])[*:2] 0.000 description 1
• 125000005677 ethinylene group Chemical group [*:2]C#C[*:1] 0.000 description 1
• YFVGSCVBPNBEPB-UHFFFAOYSA-N ethyl 8-bromo-5-[(5-fluoro-1-benzofuran-4-yl)methylamino]imidazo[1,2-c]pyrimidine-2-carboxylate Chemical compound CCOC(=O)C1=CN2C(=N1)C(Br)=CN=C2NCC1=C2C=COC2=CC=C1F YFVGSCVBPNBEPB-UHFFFAOYSA-N 0.000 description 1
• QNRJHRKYHRIXBC-UHFFFAOYSA-N ethyl 8-bromo-5-[(5-fluoro-2,3-dihydro-1-benzofuran-4-yl)methyl-[(2-methylpropan-2-yl)oxycarbonyl]amino]imidazo[1,2-c]pyrimidine-2-carboxylate Chemical compound CCOC(=O)C1=CN2C(=N1)C(Br)=CN=C2N(CC1=C(F)C=CC2=C1CCO2)C(=O)OC(C)(C)C QNRJHRKYHRIXBC-UHFFFAOYSA-N 0.000 description 1
• XYIBRDXRRQCHLP-UHFFFAOYSA-N ethyl acetoacetate Chemical compound CCOC(=O)CC(C)=O XYIBRDXRRQCHLP-UHFFFAOYSA-N 0.000 description 1
• SFNALCNOMXIBKG-UHFFFAOYSA-N ethylene glycol monododecyl ether Chemical compound CCCCCCCCCCCCOCCO SFNALCNOMXIBKG-UHFFFAOYSA-N 0.000 description 1
• 125000002534 ethynyl group Chemical group [H]C#C* 0.000 description 1
• 239000000945 filler Substances 0.000 description 1
• 239000012467 final product Substances 0.000 description 1
• 125000003983 fluorenyl group Chemical group C1(=CC=CC=2C3=CC=CC=C3CC12)* 0.000 description 1
• 125000003784 fluoroethyl group Chemical group [H]C([H])(F)C([H])([H])* 0.000 description 1
• 201000003444 follicular lymphoma Diseases 0.000 description 1
• 238000009472 formulation Methods 0.000 description 1
• 125000003838 furazanyl group Chemical group 0.000 description 1
• 125000002541 furyl group Chemical group 0.000 description 1
• LRBQNJMCXXYXIU-QWKBTXIPSA-N gallotannic acid Chemical compound OC1=C(O)C(O)=CC(C(=O)OC=2C(=C(O)C=C(C=2)C(=O)OC[C@H]2[C@@H]([C@@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)[C@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)[C@@H](OC(=O)C=3C=C(OC(=O)C=4C=C(O)C(O)=C(O)C=4)C(O)=C(O)C=3)O2)OC(=O)C=2C=C(OC(=O)C=3C=C(O)C(O)=C(O)C=3)C(O)=C(O)C=2)O)=C1 LRBQNJMCXXYXIU-QWKBTXIPSA-N 0.000 description 1
• 239000007789 gas Substances 0.000 description 1
• ZTQSADJAYQOCDD-UHFFFAOYSA-N ginsenoside-Rd2 Natural products C1CC(C2(CCC3C(C)(C)C(OC4C(C(O)C(O)C(CO)O4)O)CCC3(C)C2CC2O)C)(C)C2C1C(C)(CCC=C(C)C)OC(C(C(O)C1O)O)OC1COC1OCC(O)C(O)C1O ZTQSADJAYQOCDD-UHFFFAOYSA-N 0.000 description 1
• 150000004795 grignard reagents Chemical class 0.000 description 1
• 230000012010 growth Effects 0.000 description 1
• 239000001963 growth medium Substances 0.000 description 1
• 229940093915 gynecological organic acid Drugs 0.000 description 1
• 125000005843 halogen group Chemical group 0.000 description 1
• 201000003911 head and neck carcinoma Diseases 0.000 description 1
• 125000004446 heteroarylalkyl group Chemical group 0.000 description 1
• 125000005549 heteroarylene group Chemical group 0.000 description 1
• 125000006038 hexenyl group Chemical group 0.000 description 1
• 125000004051 hexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
• 125000005980 hexynyl group Chemical group 0.000 description 1
• 230000013632 homeostatic process Effects 0.000 description 1
• IKDUDTNKRLTJSI-UHFFFAOYSA-N hydrazine monohydrate Substances O.NN IKDUDTNKRLTJSI-UHFFFAOYSA-N 0.000 description 1
• 150000003840 hydrochlorides Chemical class 0.000 description 1
• XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical compound I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 description 1
• 238000005984 hydrogenation reaction Methods 0.000 description 1
• 125000004029 hydroxymethyl group Chemical group [H]OC([H])([H])* 0.000 description 1
• DQSRDCXTESGYKR-UHFFFAOYSA-N imidazo[1,2-c]pyrimidin-5-amine Chemical compound NC1=NC=CC2=NC=CN12 DQSRDCXTESGYKR-UHFFFAOYSA-N 0.000 description 1
• 125000002632 imidazolidinyl group Chemical group 0.000 description 1
• 125000002636 imidazolinyl group Chemical group 0.000 description 1
• 239000012535 impurity Substances 0.000 description 1
• 230000000415 inactivating effect Effects 0.000 description 1
• 125000004926 indolenyl group Chemical group 0.000 description 1
• 125000003387 indolinyl group Chemical group N1(CCC2=CC=CC=C12)* 0.000 description 1
• 125000003406 indolizinyl group Chemical group C=1(C=CN2C=CC=CC12)* 0.000 description 1
• 125000001041 indolyl group Chemical group 0.000 description 1
• 238000001802 infusion Methods 0.000 description 1
• 230000003993 interaction Effects 0.000 description 1
• 208000030776 invasive breast carcinoma Diseases 0.000 description 1
• 125000001977 isobenzofuranyl group Chemical group C=1(OC=C2C=CC=CC12)* 0.000 description 1
• 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
• 125000003384 isochromanyl group Chemical group C1(OCCC2=CC=CC=C12)* 0.000 description 1
• 125000005438 isoindazolyl group Chemical group 0.000 description 1
• 125000000904 isoindolyl group Chemical group C=1(NC=C2C=CC=CC12)* 0.000 description 1
• 238000002955 isolation Methods 0.000 description 1
• 125000002183 isoquinolinyl group Chemical group C1(=NC=CC2=CC=CC=C12)* 0.000 description 1
• 125000001786 isothiazolyl group Chemical group 0.000 description 1
• 201000005264 laryngeal carcinoma Diseases 0.000 description 1
• 230000002045 lasting effect Effects 0.000 description 1
• 230000000670 limiting effect Effects 0.000 description 1
• 125000005647 linker group Chemical group 0.000 description 1
• 208000012987 lip and oral cavity carcinoma Diseases 0.000 description 1
• 201000005296 lung carcinoma Diseases 0.000 description 1
• 239000006166 lysate Substances 0.000 description 1
• 239000012139 lysis buffer Substances 0.000 description 1
• 239000011777 magnesium Substances 0.000 description 1
• NXPHGHWWQRMDIA-UHFFFAOYSA-M magnesium;carbanide;bromide Chemical compound [CH3-].[Mg+2].[Br-] NXPHGHWWQRMDIA-UHFFFAOYSA-M 0.000 description 1
• VFZXMEQGIIWBFJ-UHFFFAOYSA-M magnesium;cyclopropane;bromide Chemical compound [Mg+2].[Br-].C1C[CH-]1 VFZXMEQGIIWBFJ-UHFFFAOYSA-M 0.000 description 1
• IUYHWZFSGMZEOG-UHFFFAOYSA-M magnesium;propane;chloride Chemical compound [Mg+2].[Cl-].C[CH-]C IUYHWZFSGMZEOG-UHFFFAOYSA-M 0.000 description 1
• 229940049920 malate Drugs 0.000 description 1
• VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
• 239000001630 malic acid Substances 0.000 description 1
• 235000011090 malic acid Nutrition 0.000 description 1
• 239000002609 medium Substances 0.000 description 1
• 230000001394 metastastic effect Effects 0.000 description 1
• 206010061289 metastatic neoplasm Diseases 0.000 description 1
• WUUOFOYBXXQAGD-UHFFFAOYSA-N methyl 1-methylpyrazole-3-carboxylate Chemical compound COC(=O)C=1C=CN(C)N=1 WUUOFOYBXXQAGD-UHFFFAOYSA-N 0.000 description 1
• 150000007522 mineralic acids Chemical class 0.000 description 1
• 230000004048 modification Effects 0.000 description 1
• 238000012986 modification Methods 0.000 description 1
• 125000002950 monocyclic group Chemical group 0.000 description 1
• ATLMSNNGGPBRBE-UHFFFAOYSA-N n,n-dimethyl-2-[4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl]ethanamine Chemical compound C1=CC(CCN(C)C)=CC=C1B1OC(C)(C)C(C)(C)O1 ATLMSNNGGPBRBE-UHFFFAOYSA-N 0.000 description 1
• YZMHQCWXYHARLS-UHFFFAOYSA-N naphthalene-1,2-disulfonic acid Chemical compound C1=CC=CC2=C(S(O)(=O)=O)C(S(=O)(=O)O)=CC=C21 YZMHQCWXYHARLS-UHFFFAOYSA-N 0.000 description 1
• PSZYNBSKGUBXEH-UHFFFAOYSA-N naphthalene-1-sulfonic acid Chemical compound C1=CC=C2C(S(=O)(=O)O)=CC=CC2=C1 PSZYNBSKGUBXEH-UHFFFAOYSA-N 0.000 description 1
• 125000001624 naphthyl group Chemical group 0.000 description 1
• 125000004923 naphthylmethyl group Chemical group C1(=CC=CC2=CC=CC=C12)C* 0.000 description 1
• 125000004593 naphthyridinyl group Chemical group N1=C(C=CC2=CC=CN=C12)* 0.000 description 1
• 238000006386 neutralization reaction Methods 0.000 description 1
• 229910017604 nitric acid Inorganic materials 0.000 description 1
• 229910000069 nitrogen hydride Inorganic materials 0.000 description 1
• 231100000252 nontoxic Toxicity 0.000 description 1
• 230000003000 nontoxic effect Effects 0.000 description 1
• 238000005935 nucleophilic addition reaction Methods 0.000 description 1
• 125000004930 octahydroisoquinolinyl group Chemical group C1(NCCC2CCCC=C12)* 0.000 description 1
• 150000007524 organic acids Chemical class 0.000 description 1
• 235000005985 organic acids Nutrition 0.000 description 1
• 230000002611 ovarian Effects 0.000 description 1
• 210000001672 ovary Anatomy 0.000 description 1
• 125000001715 oxadiazolyl group Chemical group 0.000 description 1
• 235000006408 oxalic acid Nutrition 0.000 description 1
• QNNHQVPFZIFNFK-UHFFFAOYSA-N oxazolo[4,5-b]pyridine Chemical compound C1=CC=C2OC=NC2=N1 QNNHQVPFZIFNFK-UHFFFAOYSA-N 0.000 description 1
• 239000007800 oxidant agent Substances 0.000 description 1
• 230000001590 oxidative effect Effects 0.000 description 1
• 125000000466 oxiranyl group Chemical group 0.000 description 1
• 229910052763 palladium Inorganic materials 0.000 description 1
• WLJNZVDCPSBLRP-UHFFFAOYSA-N pamoic acid Chemical compound C1=CC=C2C(CC=3C4=CC=CC=C4C=C(C=3O)C(=O)O)=C(O)C(C(O)=O)=CC2=C1 WLJNZVDCPSBLRP-UHFFFAOYSA-N 0.000 description 1
• 230000007170 pathology Effects 0.000 description 1
• 239000008188 pellet Substances 0.000 description 1
• 125000002255 pentenyl group Chemical group C(=CCCC)* 0.000 description 1
• 125000005981 pentynyl group Chemical group 0.000 description 1
• 230000000737 periodic effect Effects 0.000 description 1
• 125000004934 phenanthridinyl group Chemical group C1(=CC=CC2=NC=C3C=CC=CC3=C12)* 0.000 description 1
• 125000004625 phenanthrolinyl group Chemical group N1=C(C=CC2=CC=C3C=CC=NC3=C12)* 0.000 description 1
• 125000001791 phenazinyl group Chemical group C1(=CC=CC2=NC3=CC=CC=C3N=C12)* 0.000 description 1
• 125000001484 phenothiazinyl group Chemical group C1(=CC=CC=2SC3=CC=CC=C3NC12)* 0.000 description 1
• 125000005954 phenoxathiinyl group Chemical group 0.000 description 1
• 125000001644 phenoxazinyl group Chemical group C1(=CC=CC=2OC3=CC=CC=C3NC12)* 0.000 description 1
• NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
• 239000010452 phosphate Substances 0.000 description 1
• 125000004592 phthalazinyl group Chemical group C1(=NN=CC2=CC=CC=C12)* 0.000 description 1
• 125000003386 piperidinyl group Chemical group 0.000 description 1
• 125000004928 piperidonyl group Chemical group 0.000 description 1
• 229960005235 piperonyl butoxide Drugs 0.000 description 1
• 125000004591 piperonyl group Chemical group C(C1=CC=2OCOC2C=C1)* 0.000 description 1
• 239000010318 polygalacturonic acid Substances 0.000 description 1
• 229920002643 polyglutamic acid Polymers 0.000 description 1
• 239000013641 positive control Substances 0.000 description 1
• 235000015320 potassium carbonate Nutrition 0.000 description 1
• LPNYRYFBWFDTMA-UHFFFAOYSA-N potassium tert-butoxide Chemical compound [K+].CC(C)(C)[O-] LPNYRYFBWFDTMA-UHFFFAOYSA-N 0.000 description 1
• ZNNZYHKDIALBAK-UHFFFAOYSA-M potassium thiocyanate Chemical compound [K+].[S-]C#N ZNNZYHKDIALBAK-UHFFFAOYSA-M 0.000 description 1
• 229940116357 potassium thiocyanate Drugs 0.000 description 1
• 238000002360 preparation method Methods 0.000 description 1
• 239000000047 product Substances 0.000 description 1
• 238000004393 prognosis Methods 0.000 description 1
• 230000035755 proliferation Effects 0.000 description 1
• 125000004368 propenyl group Chemical group C(=CC)* 0.000 description 1
• 125000006410 propenylene group Chemical group 0.000 description 1
• QQONPFPTGQHPMA-UHFFFAOYSA-N propylene Natural products CC=C QQONPFPTGQHPMA-UHFFFAOYSA-N 0.000 description 1
• 125000004805 propylene group Chemical group [H]C([H])([H])C([H])([*:1])C([H])([H])[*:2] 0.000 description 1
• 125000002568 propynyl group Chemical group [*]C#CC([H])([H])[H] 0.000 description 1
• 201000001514 prostate carcinoma Diseases 0.000 description 1
• 238000011471 prostatectomy Methods 0.000 description 1
• 125000001042 pteridinyl group Chemical group N1=C(N=CC2=NC=CN=C12)* 0.000 description 1
• 125000000561 purinyl group Chemical group N1=C(N=C2N=CNC2=C1)* 0.000 description 1
• 125000004309 pyranyl group Chemical group O1C(C=CC=C1)* 0.000 description 1
• 125000003072 pyrazolidinyl group Chemical group 0.000 description 1
• 125000002755 pyrazolinyl group Chemical group 0.000 description 1
• 125000005344 pyridylmethyl group Chemical group [H]C1=C([H])C([H])=C([H])C(=N1)C([H])([H])* 0.000 description 1
• 125000000246 pyrimidin-2-yl group Chemical group [H]C1=NC(*)=NC([H])=C1[H] 0.000 description 1
• IIHQNAXFIODVDU-UHFFFAOYSA-N pyrimidine-2-carbonitrile Chemical compound N#CC1=NC=CC=N1 IIHQNAXFIODVDU-UHFFFAOYSA-N 0.000 description 1
• 125000001422 pyrrolinyl group Chemical group 0.000 description 1
• 125000000168 pyrrolyl group Chemical group 0.000 description 1
• 150000003242 quaternary ammonium salts Chemical class 0.000 description 1
• 125000002294 quinazolinyl group Chemical group N1=C(N=CC2=CC=CC=C12)* 0.000 description 1
• 125000002943 quinolinyl group Chemical group N1=C(C=CC2=CC=CC=C12)* 0.000 description 1
• 125000001567 quinoxalinyl group Chemical group N1=C(C=NC2=CC=CC=C12)* 0.000 description 1
• 125000004621 quinuclidinyl group Chemical group N12C(CC(CC1)CC2)* 0.000 description 1
• 230000005855 radiation Effects 0.000 description 1
• 239000011535 reaction buffer Substances 0.000 description 1
• 238000006268 reductive amination reaction Methods 0.000 description 1
• 230000002441 reversible effect Effects 0.000 description 1
• 238000012552 review Methods 0.000 description 1
• 238000003118 sandwich ELISA Methods 0.000 description 1
• 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
• 150000003333 secondary alcohols Chemical class 0.000 description 1
• 229910001923 silver oxide Inorganic materials 0.000 description 1
• 239000011734 sodium Substances 0.000 description 1
• 229910052708 sodium Inorganic materials 0.000 description 1
• QDRKDTQENPPHOJ-UHFFFAOYSA-N sodium ethoxide Chemical compound [Na+].CC[O-] QDRKDTQENPPHOJ-UHFFFAOYSA-N 0.000 description 1
• 235000010288 sodium nitrite Nutrition 0.000 description 1
• 235000010265 sodium sulphite Nutrition 0.000 description 1
• AKHNMLFCWUSKQB-UHFFFAOYSA-L sodium thiosulfate Chemical class [Na+].[Na+].[O-]S([O-])(=O)=S AKHNMLFCWUSKQB-UHFFFAOYSA-L 0.000 description 1
• 230000037439 somatic mutation Effects 0.000 description 1
• 125000003003 spiro group Chemical group 0.000 description 1
• 239000003381 stabilizer Substances 0.000 description 1
• 239000011550 stock solution Substances 0.000 description 1
• 239000012089 stop solution Substances 0.000 description 1
• KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 description 1
• BDHFUVZGWQCTTF-UHFFFAOYSA-M sulfonate Chemical compound [O-]S(=O)=O BDHFUVZGWQCTTF-UHFFFAOYSA-M 0.000 description 1
• 238000011477 surgical intervention Methods 0.000 description 1
• 238000001356 surgical procedure Methods 0.000 description 1
• 230000004083 survival effect Effects 0.000 description 1
• 238000010189 synthetic method Methods 0.000 description 1
• 235000015523 tannic acid Nutrition 0.000 description 1
• 229940033123 tannic acid Drugs 0.000 description 1
• 229920002258 tannic acid Polymers 0.000 description 1
• 230000008685 targeting Effects 0.000 description 1
• 235000002906 tartaric acid Nutrition 0.000 description 1
• 239000011975 tartaric acid Substances 0.000 description 1
• 229940095064 tartrate Drugs 0.000 description 1
• MABIFYRKGZJZRU-UHFFFAOYSA-N tert-butyl 2-[3-methyl-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl]pyrrolidine-1-carboxylate Chemical compound CC1=C(C=CC(=C1)C1CCCN1C(=O)OC(C)(C)C)B1OC(C)(C)C(C)(C)O1 MABIFYRKGZJZRU-UHFFFAOYSA-N 0.000 description 1
• XUULQXNFXUYKPE-UHFFFAOYSA-N tert-butyl 2-[4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl]pyrrolidine-1-carboxylate Chemical compound CC(C)(C)OC(=O)N1CCCC1C1=CC=C(B2OC(C)(C)C(C)(C)O2)C=C1 XUULQXNFXUYKPE-UHFFFAOYSA-N 0.000 description 1
• QHBCNBITHGXPID-UHFFFAOYSA-N tert-butyl 3-[4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl]morpholine-4-carboxylate Chemical compound CC1(OB(OC1(C)C)C1=CC=C(C=C1)C1N(CCOC1)C(=O)OC(C)(C)C)C QHBCNBITHGXPID-UHFFFAOYSA-N 0.000 description 1
• OCPNDBAWFUIPFR-UHFFFAOYSA-N tert-butyl 3-phenylmorpholine-4-carboxylate Chemical compound CC(C)(C)OC(=O)N1CCOCC1C1=CC=CC=C1 OCPNDBAWFUIPFR-UHFFFAOYSA-N 0.000 description 1
• LPCZUBQFSBAHID-UHFFFAOYSA-N tert-butyl 6-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-3,4-dihydro-1h-isoquinoline-2-carboxylate Chemical compound C=1C=C2CN(C(=O)OC(C)(C)C)CCC2=CC=1B1OC(C)(C)C(C)(C)O1 LPCZUBQFSBAHID-UHFFFAOYSA-N 0.000 description 1
• PJYCNAIIDIMDQQ-UHFFFAOYSA-N tert-butyl n-[(5-bromopyrimidin-2-yl)methyl]carbamate Chemical compound CC(C)(C)OC(=O)NCC1=NC=C(Br)C=N1 PJYCNAIIDIMDQQ-UHFFFAOYSA-N 0.000 description 1
• 125000005931 tert-butyloxycarbonyl group Chemical group [H]C([H])([H])C(OC(*)=O)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
• 230000002381 testicular Effects 0.000 description 1
• 125000003039 tetrahydroisoquinolinyl group Chemical group C1(NCCC2=CC=CC=C12)* 0.000 description 1
• 125000000147 tetrahydroquinolinyl group Chemical group N1(CCCC2=CC=CC=C12)* 0.000 description 1
• 125000003507 tetrahydrothiofenyl group Chemical group 0.000 description 1
• 125000000383 tetramethylene group Chemical group [H]C([H])([*:1])C([H])([H])C([H])([H])C([H])([H])[*:2] 0.000 description 1
• 125000004627 thianthrenyl group Chemical group C1(=CC=CC=2SC3=CC=CC=C3SC12)* 0.000 description 1
• 125000001984 thiazolidinyl group Chemical group 0.000 description 1
• 125000005302 thiazolylmethyl group Chemical group [H]C1=C([H])N=C(S1)C([H])([H])* 0.000 description 1
• 210000001519 tissue Anatomy 0.000 description 1
• 239000010936 titanium Substances 0.000 description 1
• CFOAUYCPAUGDFF-UHFFFAOYSA-N tosmic Chemical compound CC1=CC=C(S(=O)(=O)C[N+]#[C-])C=C1 CFOAUYCPAUGDFF-UHFFFAOYSA-N 0.000 description 1
• 231100000331 toxic Toxicity 0.000 description 1
• 230000002588 toxic effect Effects 0.000 description 1
• 230000002110 toxicologic effect Effects 0.000 description 1
• 231100000759 toxicological effect Toxicity 0.000 description 1
• VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 1
• 238000013518 transcription Methods 0.000 description 1
• 230000035897 transcription Effects 0.000 description 1
• 238000012546 transfer Methods 0.000 description 1
• 230000001052 transient effect Effects 0.000 description 1
• 238000011269 treatment regimen Methods 0.000 description 1
• GUNCFVCHRNIIBC-UHFFFAOYSA-N tributyl-(2-cyclopropylpyrazol-3-yl)stannane Chemical compound C(CCC)[Sn](C=1N(N=CC=1)C1CC1)(CCCC)CCCC GUNCFVCHRNIIBC-UHFFFAOYSA-N 0.000 description 1
• GKASDNZWUGIAMG-UHFFFAOYSA-N triethyl orthoformate Chemical compound CCOC(OCC)OCC GKASDNZWUGIAMG-UHFFFAOYSA-N 0.000 description 1
• GGUBFICZYGKNTD-UHFFFAOYSA-N triethyl phosphonoacetate Chemical compound CCOC(=O)CP(=O)(OCC)OCC GGUBFICZYGKNTD-UHFFFAOYSA-N 0.000 description 1
• CCRMAATUKBYMPA-UHFFFAOYSA-N trimethyltin Chemical compound C[Sn](C)C.C[Sn](C)C CCRMAATUKBYMPA-UHFFFAOYSA-N 0.000 description 1
• 125000005455 trithianyl group Chemical group 0.000 description 1
• 210000003932 urinary bladder Anatomy 0.000 description 1
• 238000010200 validation analysis Methods 0.000 description 1
• 231100000747 viability assay Toxicity 0.000 description 1
• 238000003026 viability measurement method Methods 0.000 description 1
• 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 description 1
• 125000001834 xanthenyl group Chemical group C1=CC=CC=2OC3=CC=CC=C3C(C12)* 0.000 description 1